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ABSTRACT
The main objective of this dissertation is to treat pancreatic cancer by developing
an amphiphilic biodegradable polymer that is capable of carrying small hydrophobic
molecules. These polymers were used to prepare micelle or nanoparticles. They were
characterized and evaluated in vitro settings and pancreatic cancer mouse model (In vivo).
In chapter 1, an overview of pancreatic cancer pathogenesis, the implicated
pathways, and current treatments will be highlighted
In chapter 2, small molecules Docetaxel (DTX) or cyclopamine (CYP) were
conjugated into methoxy poly(ethylene glycol)-block-poly(2-methyl-2-carboxyl-propylene
carbonate-graft-dodecanol)

to form polymeric conjugate of docetaxel (P-DTX) or

polymeric conjugate of cyclopamine (P-CYP). Polymeric micelles were prepared and
characterized for particle size, cytotoxicity, and synergism. Micelles containing both DTX
and CYP were assessed in an orthotopic pancreatic tumor model. The combination
treatment of P-DTX micelles and P-CYP effectively inhibited tumor growth compared to
monotherapy, either P-DTX micelle or P-CYP micelle. In immunohistochemical analysis,
tumor sections of mice treated with combined-therapy revealed a low level of tumor cell
proliferation markers, a high level of apoptotic cell markers compared to either P-DTX
micelles or P-CYP micelles.
In chapter 3, a small molecule targeting two different pathways SF2523 was
loaded into nanoparticles prepared by using a biodegradable copolymer mPEG-b-p(CBco-LA). Polymeric nanoparticles containing SF2523 were characterized for particle size,
drug loading, encapsulation efficiency, microsomal stability, and cytotoxicity in vitro.
Polymeric nanoparticles loaded with SF2523 were tested in an orthotopic pancreatic
cancer mouse model. It inhibited tumor growth effectively compared to SF2523 as a free
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drug. Mice treated with polymeric nanoparticle containing SF2523 showed better
restoration of the interstitial fluid pressure of the pancreas compared to mice treated with
SF2523 as a free drug. In the immunohistochemical assay, the Tumor section of mice
treated with Polymeric nanoparticles loaded with SF2523 showed a lower level of tumor
cell proliferation markers and a high level of apoptotic cell markers. Furthermore,
polymeric nanoparticles containing SF2523 significantly decrease the level of
desmoplasia (Collagen-1 and α-SMA) in the tumor section compared to SF2523 as a free
drug.
In chapter 4, all results from the first and second projects will be summarized and,
future research direction will be provided.
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1

CHAPTER 1. AN OVERVIEW OF PANCREATIC CANCER AND CURRENT
TREATMENT

1.1

INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is the third responsible reason for

cancer-related death in the west, with a 5-year survival rate of less than 10% [1]. Since
1975, the death rate has continually increased by 0.3% per year [2]. By 2040, the number
of incidences is expected to increase and reach 355,317 new cases [3]. The specific
causes of PDAC are not well defined; however, people who are smoker, diabetic, obese,
physically inactive, are at higher to develop PDAC [4-7]. Furthermore, 80% of PDAC
patients developed cancer between 60 and 80 years old [8].

1.2

Genetic alteration in PDAC
Around 97% of pancreatic cancer patients have gene mutations such as deletions,

amplifications, inversions, translocations, substitutions, and frameshifts [9]. Alterations of
several genes in PDAC are common, and around 70-98% of patients have these
mutations [10-12]. However, alteration of other genes is less common, and some of them
are obtained from inherited germline [13, 14]. These alterations of the gene can be
classified as an enhancer of protein functions or diminisher of protein functions.
Consequently, disruptions of protein functions lead to uncontrolled cell division,
mobility, preventions from apoptosis/autophagy, and issues with DNA repair. All the
mentioned processes promote cancer progression [9]. The most commonly mutated
genes will be discussed in the next subsection.
1.2.1

KRAS
It is a small GTPase with a molecular weight of 21 kDa and known as c-Ki-ras c-

K-ras, Ki-Ras, or K-Ras 2. It is mutated in more than 90% of pancreatic cancer patients
[Table 1.1] [15]. Its function is to bind guanosine triphosphate (GTP) and diphosphate
nucleotides (GDP), and it gets activated when binds to GTP and deactivated if binds to
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GDP. KRAS (active form) stimulates RAF family kinases, ARAF, BRAF, and RAF1[16].
Once RAFs are activated, it will activate MEK1 and MEK2 kinases, and then ERK1 and
ERK2 kinases got activated as a subsequent step. In the end, ERKs activate and
phosphorylate different nuclear-cytosolic proteins, including c-JUN and ELK1, which lead
to cell proliferation [17]. Because of KRAS alteration, uncontrolled cell proliferation and
other cellular processes will be promoted that support tumor development and metastases
[15]. Furthermore, KRAS regulates other signaling pathways such as RAL, PLC-PKC, and
PI3K-AKT. These signaling pathways are known as one of the prominent players in cancer
progression [15].
1.2.2

TP53
It is a tumor suppressor gene and knowns as P53 or antigen NY-CO-13. Its

functions are to transcriptionally activate target genes as a defense response to cellular
stress events such as DNA damages and oxidative stress. Therefore, it induces cellular
apoptosis and cell growth arrest [18]. Moreover, it increases the expression of cyclindependent kinase inhibitor (CDKN1A) and then helps in arresting cell cycle progression
[18]. This gene is one of the most commonly altered genes in pancreatic cancers, which
counts for around 70% of pancreatic cancer patients [Table 1.1] [19]. The mutated TP53
leads to failure of DNA binding ability and In subsequently, gene transcription activation
[20].
1.2.3

CDKN2A
It is a tumor suppressor gene and knowns as CDK4I, MTS-1, or p16-INK4a. It can

regulate cell cycle progression via preventing cyclinD-CDK4 and cyclinD-CDK6
complexes, which are responsible for beginning the G1/S phase transition [21]. It is one
of the most mutated genes in various types of tumors, and the incidence of alterations in
sporadic pancreatic cancer is remarkable, with 98% inactivation occurrence in pancreatic
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cancer patient cases [Table 1.1][22]. The alteration of CDKN2A happens through various
mutation mechanisms such as the promoter silencing, homozygous deletion, or loss of
heterozygosity.
1.2.4

SMAD4
It is a tumor suppressor protein and knowns as MADH4 or DPC4. It translocates

as heterotrimeric SMAD2/SMAD3-SMAD4 complex to the nucleus after activating of TGFβ
family receptors. In the end, it leads to activation and expression of targeted genes and
causes tumor growth inhibition [23, 24]. Alterations of SMAD4 happen in 50% of
pancreatic cancer cases [Table 1] [25]. The mechanisms of SMAD4 mutation occur
through homozygous deletion. It has been shown that genetic alterations of SMAD4 are
associated with poor prognosis of pancreatic cancer patients [Table 1.1] [26, 27]
1.2.5

BRCA1
It is also a tumor suppressor gene and known as RNF53. It mediates the formation

of Lys-6-linked polyubiquitin chains formation by acting as E3 ubiquitin-protein ligase [28].
It controls cellular responses to the damage of DNA. Therefore, it is essential for repairing
DNA and G2/M cell cycle progression [29]. This gene is often mutated in familial cancer
such as breast cancer, with 45% of the incidence of occurrence, ovarian cancer with 80%
of the incidence of occurrence; however, it accounts for 6.6% of pancreatic cancer patients
with familial history [Table 1.1][30].
1.2.6

BRCA2
It is a tumor suppressor gene and known as FANCD1. In the S-phase of the cell

cycle distribution. This gene is involved in double-strand break repair via activating RAD51
recombinase. Additionally, it plays a crucial role in centrosome duplication, cytokinesis,
and cell death [31]. Alterations of BRACA2 causes a high risk of developing stomach,
prostate, ovarian, breast, and familial pancreatic cancers[32, 33]. Around 7.3% of
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pancreatic cancer patients with familial background have a mutation in BRCA2, and they
are at high risk by 20-folds [13].

5

Table 1.1 Summary of genes alterations in PDAC
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1.3
1.3.1

Implicated signaling pathways in PDAC
HEDGEHOG (Hh) Signaling pathway
The Hh signaling pathway is involved in the critical role of PDAC development and

progression. The downstream signaling of this pathway is controlled through 12-pass
transmembrane protein receptor PATCHED (PTCH), which usually acts as suppressor
function over the 7-pass transmembrane protein receptor SMOOTHENED (SMO) in the
absence of the ligand. The PTCH decreases its suppression effect on SMO after binding
of Hh ligand to the PTCH protein receptor. As a result, the downstream signaling pathway
continues and becomes active. The final product of losing suppression effect on SMO
leads to release and activate of the GLI family transcription factors such as GLI1, GLI2, or
GLI3. These transcriptional factors play an essential role in cellular response processes.
Therefore, The Hh signaling pathway plays a crucial role in activating genes involved in
apoptosis and cell cycle progression.
This pathway plays an essential role in the epithelial and stromal compartments.
Several changes in the Hh signaling pathway have been shown in pancreatic tumor cells
(epithelial compartment). In the global genomic analysis, it has been shown that there is
at least one alteration in Hh signaling genes [34]. It has been found that Hh is highly
expressed in a large number of PDAC patients [35, 36]. Another compartment, which can
be affected by Hh signaling pathway is the stroma of PDAC. The Hh signaling pathway is
triggered in a stromal cell connected with a pancreatic cancer cell that has a high
expression level of Hh ligands such as SHH or IHH, suggesting a paracrine function [37,
38]. Another study in an orthotopic model from PDAC cells overexpressing SHH showed
that a high level of desmoplasia (stroma), whereas the level of stroma was low after
treatment with a SHH-specific antibody [39]. Moreover, the SMO has a high expression in
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cancer-associated fibroblasts, and thereby activation of the Hh pathway leads to GLI1
overexpression [40]. In Pdx-1-Cre; TrpR172H/+; KrasG12D/+ mouse model, a group of
scientists, found a low level of stroma and collagen-1 deposition in mice treated with a Hh
inhibitor [41]. Taken together, these results suggest that the Hh signaling pathway plays
a significant role in tumor growth and desmoplasia support.
1.3.2

NOTCH signaling pathway
NOTCH is mainly active in the embryogenesis stage. However, this pathway has

been seen to be active in various types of cancers, including PDAC. The primary function
of NOTCH in development is to prevent the terminal differentiation of cells until appropriate
[42]. In addition, it maintains the population of undifferentiated cells in normal tissue to
serve as s progenitor cells. The interaction between transmembrane ligands of
neighboring cells and NOTCH receptors either NOTCH-1 or NOTCH-2 leads to the
cleavage of the intracellular domain of the receptors by an enzyme called γ-SECRETASE.
After that, the cleaved part of the receptor moves in the cytoplasm and crosses the nuclear
membrane to interact with transcription factors to stimulate the expression of targeted
genes. It has been shown that high expression of NOTCH receptors and ligands in early
PanIN lesions compared to the normal pancreas [43]. It was seen that high expression of
NOTCH in pancreatic cancer is not only needed for tumor initiation but also required for
tumor maintenance [44]. The NOTCH-1 and NOTCH-2 have different functions on
pancreatic cancer. It has been found that the NOTCH-1 was expressed on normal acinar
cells, whereas it was rarely expressed in PanIN lesions; however, NOTCH-2 was found in
the ductal cells [45]. The loss of NOTCH-2 in the KrasG12D mouse model was seen to
inhibit PanIN progression [45]. In the Pdx1-Cre; KrasG12D; p53lox/+ mouse model, the
NOTCH signaling pathway was seen to be overexpressed, which results in support of the
progression of PDAC lesions, and treating these mice with GSI ( γ-SECRETASE inhibitor)

8
showed inhibition of early-stage progression [46]. Therefore, the NOTCH signaling
pathway plays a critical role in promoting PDAC tumorigenesis.
1.3.3

WNT Signaling pathway
The WNT signaling pathway plays a primary role in cell growth, development, and

differentiation. This pathway is activated when ligands interact with the WNT protein
receptor on the cell membrane. This interaction leads to β-Catenin release onto the
cytoplasm. Generally, β-Catenin is inactive. This form is activated by phosphorylation by
GSK3-β kinase and binding to axon and APC. This phosphorylation enhances β-Catenin
ubiquitination and degradation by proteasomes. A free form of β-Catenin can cross
through the cytoplasm and translocate into the nucleus to interact with transcription factors
T-cell factor (TCF) and lymphocyte-enhancer (LEF) to activate target genes. A high level
of β-Catenin has been seen in most PDAC but was not high in the normal pancreas [47,
48]. The siRNA that knockdowns β-Catenin, decrease the pancreatic cancer proliferation
by increasing the apoptosis [48]. Thus, the WNT Signaling pathway supports tumor
growth, development, and differentiation.
1.3.4

The nuclear factor-κB (NF-κB) proteins
NF-κB is a family of transcription factors that correlated with controlling

inflammatory responses, genes responsible for cell proliferation, cell apoptosis, and cell
development. These transcription factors regulate both tumor and stromal cells of PDAC.
In the normal state, NF-κB factors including c-Rel, p100/p52, p65 (RelA0), p105/p50, and
RelB are present in the cytoplasm of cells as homodimeric or heterodimeric form. These
factors typically are inactive form because of their linkage with IκB-α, which prevents them
from being localized in the nucleus. Once the appropriate signals are received by cells, it
allows phosphorylation and degradation of IκB-α, followed by a nuclear movement of NFκB to regulate transcription of the targeted genes [49]. A study has shown that the
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incidence of PDAC is highly increased in patients who have chronic pancreatitis compared
to those who have not [50].
Furthermore, the presence of immune cells in the tumor microenvironment (TME)
is associated with the promotion of NF-κB activity in stromal cells due to the secretion of
cytokines. Thereby, it will activate NF-κB in the tumor cells, which support tumor
progression [49]. It has been demonstrated that the NF-κB subunit RelA is highly activated
in PDAC; however, it is not activated in normal pancreatic cells [51]. Another study has
revealed that NF-κB subunits such as p105, p100, and cRel have a high-level of
expression in PANC-1 and BxPC-3 cells compared to nonmalignant cells [52]. Therefore,
it is evidence that NF-κB factors play a significant role in supporting PDAC.
1.3.5

C-MYC
C-MYC is an essential regulator of several aspects of cell growth. It is an oncogene

that facilitates cell growth and cell transformation [53]. It can activate or repress the
transcription of the targeted genes based on the other cellular stimuli, and it provokes the
transcription of genes that involved in cellular metabolism, cell cycle progression, and
inhibition of checkpoint [54]. The activation of C-MYC can be achieved by several signaling
pathways, such as WNT [54]. Using Ela-1-myc transgenic mice showed a high expression
C-MYC support the development of acinar cell lesions, and ductal cell lesions [55].
Another study showed that a 30% amplification of C-MYC was seen highly increased in
PDAC patients, and most of them have concurrent gene activations that support tumor
growth [56]. The nuclear factor of activated T-cells (NFAT) is a family of transcriptions
factors that are implicated to be active in C-MYC-dependent growth of pancreatic cancer.
It has been shown that NFAT is overexpressed in pancreatic cancer and supports
tumorigenesis through activating the C-MYC gene expression [57]. Nuclear translocation
of NFAT and interaction with C-MYC promoter increases the activity of p300-dependent
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histone acetylase, then binding of other factors to stimulate the activity of C-MYC
transcription [58].
1.3.6

Epidermal Growth Factor Receptor (EGFR)
EGFR family consists of a cytoplasmic receptor tyrosine kinases that contain

human EGF receptor or HER1 (ErbB-1 or EGFR1), Her2 (ErbB-2 or EGFR2), Her3 (ErbB3 or EGFR3), and Her4 (ErbB-4 or EGFR4). Typically, the interaction between a ligand
and receptor results in conformational changes in the receptor (dimerization) and
activation that felicitate the initiation of the downstream signaling pathways. This can
induce other signaling pathways such as phosphoinositol-3 kinase (PI3K), Ras, and
phospholipase C pathways. These pathways have intersecting players, which play a vital
role in stimulating the transcriptions of targeted genes. These genes promote cell growth,
proliferation, and survival [59]. Increased expression of the EGFR2 has been revealed to
be existent in pancreatic cancer cells [60]. Researchers have evaluated a sample of
human PDAC tissues and shown high expression of EGFR2 [60, 61]. The expression of
EGFR2 is significantly higher in PanIN lesions and carcinoma compared to normal
pancreatic ducts [62]. Based on what was mentioned, EGFR has an essential role in
PDAC progression and development.
1.3.7

PI3K signaling pathway
The PI3K signaling pathway is a vital downstream target of the rat sarcoma virus

(Ras) family. This family is a group of proteins that are responsible for cell proliferation. It
was estimated that 60% of PDAC cases have dysregulation of the PI3K signaling pathway
[63-66]. The PI3K belongs to a family called lipid kinase, that respond to trigger from the
Ras family to regulate several cellular responses such as cell growth, motility,
transformation, proliferation, and survival [67, 68].
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1.4

Pathogenesis of PDAC
The PDACs are derived from the epithelial cells that are present in the pancreatic

duct (gland-like shape) [69]. The development of PDAC can be achieved by developing
the hyperplastic lesions called pancreatic intraepithelial neoplasias (PanINs) [70]. PanINs
are histologically defined as the microscopic mucinous pancreatic ductal lesions (<0.5 cm)
[71]. According to the degree of nuclear and cellular atypia, this non-cancerous lesion is
sub-classified into low- (PanIN-1A/B) to high- (PanIN-3) degree lesions [72]. This process
is accompanied by huge genetic alterations, which accumulate over time and drive PDAC
development through PanIN stages (PanIN1–3). In the PanIN-1 stage, miRNAs
(oncogenic) are overexpressed. The KRAS is alerted, and stromal factors are activated
[73]. In the PanIN-2 stage, Mucin 1 (MUC1) is highly expressed, and the p16/CDKN2A
gene has mutations. Finally, PanIN-3 stage is associated with mutation in TP53, BRCA2,
and SMAD4 [74-77]. Furthermore, the TME has a critical role in PDAC pathogenesis and
failures of therapeutic attempts. PDAC composed of different types of cells such as
fibroblasts, immune cells and endothelial cells, which serve different roles in supporting
tumorigenesis [78-80]. A CXCL12 is a cytokine produced by stromal-derived cells, which
is taken up by pancreatic tumor cells and supports tumor growth invasion and
chemoresistance. Pancreatic cancer cells secreted SHH ligand that stimulates
desmoplasia of the tumor through a paracrine mechanism, and boost pancreatic
tumorigenesis [81, 82]. In contrast, It has been reported that depletion of stroma makes
the disease worse [83, 84]. The mechanism of stroma in supporting tumor growth is still
unanswered. Therefore, the dual effect of TME open the door for scientists to investigate
how TME supports the PDAC progression.
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1.5
1.5.1

Characteristic of PDAC
Chemoresistance
Most of the researches on chemoresistance of PDAC focuses on gemcitabine [85].

Resistance to chemotherapies is one of the primary barriers in the treatment of the PDAC.
Chemoresistance can be classified into intrinsic or acquired mechanisms. The intrinsic
mechanism defines as the ability of cancer cells to bypass the toxic effect of the
chemotherapies through drug breakdown, change the expression of drug target, reduce
the drug transporter channels across the cell membrane, or decrease the interaction
efficiency between drug and its molecular target [86, 87]. This resistance mechanism can
be mediated by nuclear receptors such as sxr or ATP-dependent membrane transporters
[88].Moreover, some cellular metabolic (ceramide glycosylation) processes reduce the
efficacy of chemotherapies [89].
On the other hand, the acquired mechanism is irresponsive to chemotherapies
after multiple treatments. This mechanism is influenced by environmental and genetic
factors that help in the development of chemo-resistant cancer close or promote
enzymatic mutations that play an essential role in metabolic pathways [87, 90].

1.6

Factors implicated in developing resistance to chemotherapies
The development of resistance to chemotherapies in PDAC is multifactorial and

might be attributed to the interaction between cancer stem cells (CSCs), non-coding
RNAs, and TME.
1.6.1

Cancer stem cells (CSCs)
CSCs are a small subclass of tumor cells that act as the driving force of cancer

development. CSCs have some distinct features, such as their ability to self-renew, initiate
cancer development, and develop drug resistance. CSCs develop chemoresistance
against gemcitabine and 5-FU through overexpression of c-Jun N-terminal kinases (JNK)
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[91]. Another study has shown that retinoic acid (RA) was able to decrease the mRNA
expression of CSCs markers such as CD44, CD24, CD133, and ALDH1 [92]. Pancreatic
CSCs have a high expression of EMT activator zinc finger E-box binding homeobox 1
(ZEB1). ZEB1 controls the chemoresistance and stemness of CSCs by epigenetic
silencing of the miR-203 [93, 94]
1.6.2

Non‑coding RNAs
It is an RNA molecule, which is transcribed from DNA, such as miRNA. The

miRNAs can regulate gene expressions in most of the cellular biological processes. They
also play an essential role in developing resistance against standard chemotherapies [95101]. It has been shown that the downregulation of miR‑497 might lead to
chemoresistance; however, the upregulation of miR‑497 increases pancreatic cancer
sensitivity to gemcitabine and erlotinib [95] . Moreover, Overexpression of miR-33a
enhances the sensitivity of pancreatic cancer cells to standard chemotherapy
(gemcitabine), and it also inhibits tumor growth by blocking of Pim‑3 kinase expression
[96]. Another study showed that both miR‑29a and miR‑330‑5p serve as tumor
suppressor genes by decreasing MUC1 expression level and increasing pancreatic cancer
cells' sensitivity toward gemcitabine [97].
1.6.3

The tumor microenvironment
It is an interstitial tissue that surrounds cancer cells and, it consists of cellular

compartments such as nerve cells, endothelial cells, fibroblasts, pancreatic stellate cells,
and inflammatory cells and non-cellular components such as fibrous proteins and
proteoglycans [102]. These components interact with cancer cells and promote
desmoplastic reactions, which prompt chemoresistance [103]. Around 90% of the tumor
volume is the fibrous stroma that acts as a barrier for proper delivery of chemotherapeutic
agents to cancer cells. However, depletion of the stroma is associated with tumor
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progression, which means stroma has some components that inhibit tumor growth [84,
104]. Some soluble proteins that are secreted by fibroblast in the stroma are implicated in
promoting chemoresistance in cancer cells [105]. One study has shown that the SOM230
analog activates somatostatin receptor 1 in cancer‑associated fibroblasts and inhibits
protein synthesis by rapamycin/4E‑BP1 pathway. This activation leads to improving the
efficacy of gemcitabine treatment [105].
1.6.4

Pancreatic stellate cells (PSCs)
These cells are one of the critical components of the tumor stroma and play a

significant role in cancer proliferation. There are two different states (quiescent state PSCs
or activated state). The quiescent state usually presents in the normal tissue; however, it
can be activated via the inflammatory signals (e.g., TGF-β1, and present as a
myofibroblasts-like phenotype [102]. Once those PSCs got activated, it can secrete the
ECM proteins including laminin, fibronectin and collagen, resulting in the formation of a
dense desmoplasia. PSCs support tumor growth, chemoresistance in the pancreatic
cancer cells. One study performed using the co-culture methodology of PANC-1 or BxPC3 cells with PSCs showed increased resistance to gemcitabine by increasing the
expression of hairy and enhancer of split-1 (Hes1) via the NOTCH pathway. The
knockdown of the NOTCH or Hes1 leads to reverse chemoresistance [106].
Furthermore, PSCs produce soluble stromal cell-derived factor-1α, that
suppresses the apoptotic effect of gemcitabine in pancreatic cancer cells (PANC-1)
through binding to C-X-C chemokine receptor type 4 to activate FAK-protein kinase B
(AKT) and ERK ½ pathways [107]. The vitamin D receptor is expressed on PSCs, and it
gets activated after its interaction with vitamin D receptor ligand and regulates tumor
stroma reprogramming thorough restoring PSCs nature state [108]. The activated PSCs
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have a low expression level of miR-29a and miR-29b. These two miRNAs are associated
with a high ECM deposition [109].

1.7
1.7.1

The FDA approved treatment for PDAC
Gemcitabine (GEM)
GEM is an analog of deoxycytidine that is a pyrimidine antimetabolite [110]. This

compound is a pro-drug, once it gets inside the cells; it is converted to the active forms
gemcitabine diphosphate and gemcitabine triphosphate by phosphorylation using
deoxycytidine kinase. Both forms can incorporate into the DNA, resulting in inhibition of
the processes that are required for DNA synthesis [111]. It showed better clinical
outcomes in treating pancreatic cancer patients over 5-FU [112]. Even though it suffers
from being metabolized in the human body (short-half-life) and less cell membrane
permeability, it received the FDA approval to be used as a treatment option for pancreatic
cancer patients [113, 114]. It has been the first option for two decades until combination
chemotherapies showed a better survival rate and longer median overall survival than
GEM [115-117]. These two combinations ( FOLFIRINOX or gemcitabine/nab-paclitaxel)
become the first-line treatment for advanced pancreatic cancer [118].
1.7.2

FOLFIRINOX
This combination regimen consists of 5-FU, leucovorin, oxaliplatin, and irinotecan.

The mechanism of action of 5-FU is to inhibit thymidylate synthase that is important for
pyrimidine thymidine synthesis (required for DNA replication). Leucovorin is similar to folic
acid, and not chemotherapy by nature. It is added to the chemotherapy regime to improve
the anticancer effect of 5-FU. Oxaliplatin is platinum-based chemotherapy and exhibits the
anticancer effect through DNA damage by forming the DNA lesions, stop DNA synthesis,
and block RNA synthesis [119]. Irinotecan acts as an antineoplastic enzyme inhibitor. It
stops DNA strand re-ligation through binding to topoisomerase I-DNA complex and
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initiates double-strand DNA damage and cell killing [120]. The superiority of FOLFIRINOX
over GEM was after some pre-clinical and clinical studies, which suggested the synergistic
effect and no overlapped toxic effect [121-128]. The PRODIGE6 is a clinical trial, which
compared FOLFIRINOX to GEM. There were 171 patients in each arm, and FOLFIRINOX
arm has improved the median overall survival by around 4.3 months [116]. It is well known
that FOLFIRINOX causes a grade 3-4 adverse events such as neutropenia, febrile
neutropenia, thrombocytopenia, diarrhea, and peripheral neuropathy compared to GEM;
however, the quality of life of the patient was not statistically significant compared to GEM
[129].
1.7.3

Gemcitabine/nab-Paclitaxel
Another clinical trial study, which makes the combination of GEM and nab-

Paclitaxel better option for treating pancreatic cancer as first-line therapy, is called the
MPACT study. The median overall survival was around 8.5 months for patients treated
with combined-therapy of GEM and nab-paclitaxel; however, the median overall survival
was around 6.7 months for patients treated with GEM alone [117]. In terms of toxicities,
patients treated with combination therapy experienced toxicity more than GEM alone.
These toxicities are as follow neutropenia, febrile neutropenia, fatigue, peripheral
neuropathy, and diarrhea. In comparison between GEM/nab-paclitaxel and FOLFIRINOX
regarding neuropathy toxicity, GEM/nab-paclitaxel causes less neuropathy compared to
FOLFIRINOX.
1.7.4

Gemcitabine and erlotinib
The EGFR is highly overexpressed in the pancreatic tumors, and it plays a vital

role in tumor progression [130, 131]. The overexpression of this molecule is correlated
with a low prognosis. A combination of gemcitabine and erlotinib was tested in phase 3
clinical trial and showed moderate and significant improvement in overall survival 6.2
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months compared to 5.9 months in gemcitabine arm [132]. The FDA approved this
combination after the phase III clinical trial. This combination has become a good option
for treating advanced and unrespectable pancreatic tumor patients [133].
1.7.5

Liposomal irinotecan (nal-IRI), 5-Fu, and leucovorin
Nal-IRI is a liposomal formulation of irinotecan. This chemotherapy acts as a

topoisomerase I inhibitor [134]. It has been shown that nal-IRI have a better therapeutic
profile than conventional irinotecan because the active metabolite (SN-38) was achieved
at a lower dose in liposomal formulation compared to free form [135]. The combination of
nal-IRI with 5-fluorouracil and leucovorin was approved by the FDA for metastatic PDAC
patients, who failed on gemcitabine-based therapy. Based on NAPOLI-1 trial (phase III),
this combination significantly improved the overall survival rate of 6.1 months compared
to 4.2 months in 5-fluorouracil and leucovorin arm [136].

1.8

The nanotechnology in cancer
It is the idea that small sized materials can be designed and introduced to the

human body in order to perform cellular damages or repairs at molecular levels [137]. The
ultimate goal of using nanotechnologies/nanomedicine in cancer treatment is to improve
drug absorption and permeability plus controlled released manner of the drug and
increase site specificity [138]. The nanotechnologies/nanomedicine are capable of
interacting with the biological molecules inside cells or outside cells, which is useful for
cancer

therapy

and

diagnosis

[139,

140].

The

advantages

of

nanotechnologies/nanomedicine over the traditional excipient approach such as
emulsions and surfactants are that avoid physiological barriers, prevent fast drug
metabolism or degradation, can passively target the drug to tumor vasculature by the
enhanced permeability and retention phenomenon (EPR), and can actively target to
specific site after functionalizing with specific target moiety [141-143].
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Furthermore, the nanotechnology carriers are easy to be synthesized,
inexpensive, and modifiable to perform specific applications. For example, adding a
reactive functional group can help in incorporating targeting moiety to improve the delivery
to specific sites or linking fluorescent moiety that will be helpful in better diagnosis. It has
been shown that loading or incorporating the cytotoxic agents in nanocarrier can improve
tumor penetration and enhance the therapeutic efficacy [144-146]. Loading anticancer
drugs in nanocarrier has several benefits. First, it increases the circulation time of the
loaded drug and protects the loaded drug from being cleared quickly by the kidney or liver.
Second, the small size of the nanocarrier causes passive extravasation of drug called the
EPR phenomenon. It happens when an improper formation of vasculatures in the tumor
site. These vasculatures have tiny pores where nanoformulations can passively diffuse
inside the tumor and accumulated because of poor lymphatic drainage on the tumor site.
Therefore, these nanoformulations are less likely to go back to systemic circulation; as a
result, a higher drug concentration at the tumor site is accomplished. Finally, the side
effect of co-solvents is absent because hydrophobic drugs can be effortlessly loaded or
encapsulated onto the nanoparticle systems.
Active targeting is another advantage of using nanoformulations. Specific targeting
moieties such as antibodies, aptamers, or peptides can be attached to the surface of the
nanocarrier that would lead to favored binding on specific receptors on the targeted cell.
Thus, this interaction ensures that nanoformulation reach the targeted cells and avoid
other cells, leading to more effective treatment [141]. There are plentiful researches on
using nanocarriers for treating different type of cancers such as prostate, colorectal,
ovarian, breast cancer [147-152]. In the next section, we will highlight the uses of different
types of nanocarriers in pancreatic cancer.
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1.8.1

Polymer-Drug Conjugates
The polymer-drug conjugates consist of chemotherapy molecules or targeting

moieties that are conjugated onto the polymers by forming a covalent chemical bond
between chemotherapy molecules or targeting moieties and a hydrophilic polymeric
carrier. They could be applied in tumor diagnosis or detection [153]. Most of the
chemotherapeutic agents are hydrophobic, that feature acts as a challenge or barrier
against clinical trial testing. Therefore, conjugating the chemotherapy into the backbone
of hydrophilic polymer would lead to the core-shell aggregate formation by which the
lipophilic drug exists in the hydrophobic micellar core. Consequently, this conjugation
enhances the water solubility of chemotherapies and alters the pharmacokinetic profile of
chemotherapies at the whole body and even subcellular level [154, 155]. Thus, It improves
the therapeutic effect of chemotherapies. There are many good examples of this method
has been reported in the literature. SN-38 is an active metabolite that can not be
administered as a free form to patients because of its poor solubility in water and other
co-solvents [156]. Conjugating of SN-38 onto the poly(ethylene glycol) based polymer
improves its water solubility and bioavailability. Furthermore, vismodegib (GDC-0449) was
encapsulated into the lipophilic core that offers the dual therapy strategy. This dual system
showed in vitro that GDC-0449 (Hh inhibitor) restored fibroblast, which is responsible for
SN38 resistance. Finally, the potent in vivo chemotherapeutic effect was achieved after
using the conjugation approach [154].
1.8.2

Amphiphilic Polymers
The amphiphilic polymers consist of both lipophilic and lipophobic parts. They

spontaneously or favorably aggregate to form the core-shell structures in the aqueous
solution [157]. This polymer is extensively used in drug delivery to improve the water
solubility of the hydrophobic drug inside the lipophilic core of the formed aggregate. Based
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on the molecular formation, there are many different architectures of amphiphilic polymers,
which will be discussed in the following paragraphs.
1.8.2.1 Block Copolymers
They are the most common type of amphiphilic polymers. This kind of polymers is
made-up of polymerizing of two or more kinds of monomer units in the linear style [158].
In general, one hydrophilic and one hydrophobic monomer are polymerized, which leads
to the amphiphilic diblock copolymer such as poly(ethylene oxide)-block-poly(lactic acid)
(PEO-b-PLA) [159]. In aqueous environments, the block copolymers can spontaneously
form polymeric micelles. The micelles characters depend on the hydrophilic and
hydrophobic monomer blocks. Poly(ethylene glycol) is the most commonly used
hydrophilic polymer because it is biocompatible, offers efficient steric hindrance protector,
increases the circulation time of the micelles in the blood [160-162]. Polymeric micelles
stability depends on the molecular weight and types of the hydrophobic block. Higher
molecular weight and more hydrophobic blocks have greater stability than low molecular
weight and less hydrophobic block [141]. There are several reports in the literature
showing that using mixed micelles to incorporate various chemotherapeutic agents such
as paclitaxel, 5-fluorouracil, gemcitabine, and doxorubicin improves pancreatic cancer
treatment [163].
1.8.2.2 Graft Polymers
They are branched polymer consist of the hydrophilic homopolymer backbone and
hydrophobic pendant moieties attached to the hydrophilic backbone [164]. This type of
polymer favorably forms aggregates in aqueous solutions due to the reduction in Gibbs's
free energy. It was shown in the literature that developing a chitosan grafted polymer with
poly(ethyleneimine) and candesartan conjugate and complexed with w-p53 genes are
beneficial for targeting pancreatic cancer cells [165].
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1.8.2.3 Dendrimers
They are a grouping of repetitive, very branched, and symmetrical polymers.
Dendrimer branches act as a selective door to control the entry of the small molecules
and show the smallest size by far [141]. The number of branches points is traced from the
center of the dendrimer to the periphery of the dendrimer, and it is called the generation
[166]. The solubility of the dendrimer can be managed by the terminal groups on the
dendrimer border [167]. These terminals also can be used as an anchor to link with
polymers, antibodies, and drugs [168, 169]. The mechanism of aggregation depends on
the molecular composition of the system, and it could include hydrogen bonding,
electrostatic, or hydrophobic interaction [170]. The hydrophobic drugs can be loaded in
the hydrophobic core of the dendrimers, and achieve sustained release profile [171]. It
has been shown that poly(amidoamine) (PAMAM) dendrimers with the conjugation of
hyaluronic acid improve the water solubility of 3,4-difluorobenzylidene curcumin [172].
1.8.2.4 Smart Polymers
Smart polymer or stimuli-responsive polymer undergoes conformational changes
due to the changes in the surrounding environmental factors. These factors can be either
biological (biomolecules), physical (light, temperature, ultrasound), or chemical (pH) [173176]. It is known that the metabolic rate of the tumor tissue is higher than the healthy
tissue. The temperature on tumor tissue is ranged from 40-44 oC [177]. In 2017, a group
of people developed a thermos-responsive copolymer composed of hydrophobic blocks
and hydrophilic thermos-responsive blocks ( poly[(di(ethylene glycol) methyl ether
methacrylate-co-poly(ethylene glycol) methyl ether methacrylate 300)-b-poly(2-ethylhexyl
methacrylate)] [poly(diEGMAco-OEGMA300)-b-PEHMA]). This polymer could easily selfassembled in the aqueous environment, and was used to deliver gemcitabine derivatives
and paclitaxel. The conformational change happened when the temperature reaches 40
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C. This study showed that thermos-responsive polymers have a high potential in

pancreatic cancer treatments [178].
Another type of smart polymer is pH-responsive micelles. It has been reported that
the pH of the tumor tissue is around 6.75, while the pH of the healthy tissue is around 7.4
[175, 179]. A group of people in Canada developed amphiphilic polymers that can selfassembled and encapsulate the curcumin. Once the reduction in pH occurs, the micellar
structure was destabilized, and drug release occured. The authors have concluded that
this system has a high potential for delivering chemotherapies specifically to cancer cells
with the help of pH-responsive polymers [180].
1.8.3

Albumin
It is well known as an excellent drug delivery system for hydrophobic drugs [181].

The advantage of albumin is that long half-life around 19 days [182]. In 2013, the FDA
approved Abraxane®, which nanoparticle-albumin bound paclitaxel to treat metastatic
pancreatic cancer patients. An international study (Phase III study) showed that the
combination of Gemcitabine and Abraxane® significantly improved the overall survival rate
in pancreatic cancer patients compared to gemcitabine only [117].
1.8.4

Inorganic Nanoparticles
It has useful properties that are suitable for novel systemic delivery due to their

electrochemical, optical, and electrical properties [183]. In the next sections, the list of
inorganic nanoparticles will be discussed, and their applications in pancreatic cancer
treatments.
1.8.4.1 Carbon Nanotubes (CNTs)
They have several advantages that made them useful for the drug delivery system.
The high degree of biocompatibility, high target specificity, and target sensitivity are the
main reason for CNTs to be attractive as a delivery system in pancreatic cancer [184,
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185]. CNTs can be used to deliver a broad range of molecules such as small molecules,
small peptides, proteins, vaccines, nucleic acid, and carbohydrates. These molecules can
be loaded onto the inner cavity of the tubes, or linked onto the outer surface of the tubes.
One study showed that encapsulating of the MRI contrast agent gadolinium nanoparticles
with CNTs could map and ablate the primary tumors and metastatic lymph nodes [186].
1.8.4.2 Quantum Dots
They are semiconductor crystal in nano-sized range and have distinctive electronic
and optical features. They also exhibit intensive and bright fluorescence that is not
quenched easily compared to conventional fluorescent labels [187]. The quantum dots
have different applications in pancreatic cancer (therapeutics or diagnostics). One study
showed that coating Cadmium telluride quantum dots (CdTeQDs) with mercaptopropionic
acid could eradicate pancreatic cancer cells after UV illumination through generating
reactive oxygen species (ROS) [188]. Another application is the pancreatic cancer
diagnosis. The pancreatic cancer diagnosis is a challenge due to the absence of apparent
biomarkers or detection methods for these markers. A group of people in South Korea has
developed a QDs containing Cadmium Selenide (CdSe) in the core and (Cd, Zn)S in the
shell. The surface of the QDs was conjugated with claudin-4 and mesothelin (MSLN), and
prostate stem cell antigen (PSCA) to ensure the target specificity to pancreatic cancer
cells. The QDs showed a high target selectivity with low non-specific binding level [189].
These results offer a new method of diagnosis of pancreatic cancers.
1.8.4.3 Iron Oxide Nanoparticles (IONP’s)
They have various applications in the medical field, such as cell labeling, magnetic
cell sorting, drug transportation, cancer detection, and cancer treatment [190]. They are
different shapes for IONP’s including rods, cubic, hexagonal, and spherical. Furthermore,
IONP’s with particle size less than 20 nm are superparamagnetic [191, 192]. This feature
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allows the IONPs to be beneficial as MRI contrast agent that would be useful in cancer
imaging and diagnosis [193]. Arachchige’s group has developed dextran-coated IONPs.
This system was tagged with red fluorescing doxorubicin and green fluorescing fluorescein
to track the nanoparticles inside the MIP PaCa-2 cells. This study revealed that the cellular
uptake of doxorubicin was 20 times higher than the free drug [194]. Another group has
developed poly (lactic-co-glycolic acid) (PLGA) coated with 17AAG (heat shock protein
inhibitor) and loaded with IONPs. This system has decreased the cell viability by 75%
compared to control cells due to magnetic hyperthermia subjected to MIA PaCa-2 cells
[195].
1.8.4.4 Hybrid Iron Oxide-Gold Nanoparticles
The hybrid nanoparticles consist of gold shells covering the iron oxide core. These
nanoparticles have a mix of physical characters including magnetism (iron oxide core) and
nano-heater plus biocompatibility (gold shell) [141]. Larson’s group has reported that using
a GoldMag, which is hybrid nanoparticles, decreased the cell viability of Panc-1 by 47%;
however, after cellular uptake of the nanoparticles and irradiation for 5 mins at 808 nm,
only 2.3% of the cell was viable because the thermal raised to 79.51 oC. Therefore, the
mixture of thermal generation and cytotoxicity of hybrid nanoparticles showed a significant
reduction in cell proliferation of Panc-1 cells [196]. Hoskins’s group have developed hybrid
iron nanoparticles coated with poly(ethylene glycol) that have potential as a theragnostic
because of its capability to image using MRI, deliver drugs, heating up after irradiation.
They showed in this study hybrid nanoparticles increase the thermal by 9 oC, and heat
shock proteins (HSPs), that indicate tumor cells have stresses because of generated heat
[197]
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1.8.4.5 Gold Nanoparticle
They are useful vehicles for targeted delivery systems. They also have various
shapes such as tetrapods, rods and spheres. Gold metal is relatively non-toxic and
resistant to corrosion, oxidation, and acidic condition because it is noble metal. Due to its
biocompatibility, easy to synthesize and carry drugs, gold has powerful tools in pancreatic
cancer therapy. Additionally, absorbing near-infrared (NIR) radiation, and generating heat
through surface plasmon resonance (SPR) make the gold as a powerful tool to eradicate
tumor but not healthy tissue because the laser emitting NIR radiation can be targeted to
an area (pancreas) where the gold nanoparticles are located.[198-201]. It was reported
that gold nanoparticles could interfere with mitochondrial electron transfer chain in
pancreatic cancer cells (1.4E7 cells) and depolarize mitochondrial cell membranes,
resulting in cell lysis. Further, these nanoparticles inactivated the Bcl-2 anti-apoptotic
proteins after cellular uptake and irradiation nanoparticles [202]. Another study showed
that gold nanoparticles could interrupt the communicating between pancreatic cancer cells
(Panc-1 or AsPC-1) and fibroblast cells, resulting in reprograming the TME and hindering
tumor growth [203].
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2.1

Chapter 2. Coadministration of Polymeric Conjugates of Docetaxel and
Cyclopamine synergistically inhibits Orthotopic Pancreatic Cancer Growth and
Metastasis
Introduction
Pancreatic ductal adenocarcinoma (PDAC) is among the most devastating

diseases, with a 5-year survival rate of less than 6% [204] . The curative therapeutic option
is surgical resection; however, because of the lack of early symptoms, the vast majority of
patients present in the clinic at a very advanced stage, and less than 25% of patients are
surgically resectable by the time of diagnosis [205, 206]. By 2030, pancreatic cancer is
expected to be the third leading cause of cancer-related death [207]. In 1996, the Food
and Drug Administration (FDA) approved gemcitabine hydrochloride as a first line
chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma, but its
clinical outcomes are indigent due to inefficient delivery and rapid metabolic inactivation
[208]. In addition, a new combination therapy FOLFIRINOX (5-fluorouracil [5-FU],
leucovorin, irinotecan and oxaliplatin) has shown improvement in overall survival
compared to gemcitabine alone. However, there were significantly more grade 3-4
toxicities such as cytopenia and neutropenia fever with this therapy [209].
One of the characteristic features of PDAC is development of a dense
desmoplastic (abundant fibrotic stroma around the cancer cells) that affect tumorigenesis,
therapy resistance and possibly metastasis of tumor cells [210]. Desmoplasia is composed
of extracellular matrix (ECM) including collagen and fibronectin. These proteins play a vital
role in supporting cancer cell growth, invasion and metastasis [155, 211]. Hedgehog (Hh)
signaling pathway promotes desmoplasia by causing pancreatic stellate cells to
differentiate into myofibroblasts, which hinder the delivery of chemotherapeutic agents by
forming a barrier from fibrotic cells around the tumor cells. By blocking the Hh pathway to
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inhibit desmoplasia formation, extravasation of chemotherapeutic agents can be
facilitated, and chemotherapeutic activity may be improved.
Cyclopamine (CYP) is a natural steroidal alkaloid, which can inhibit the Hh
signaling pathway by blocking the 12-transmembrane protein smoothened (Smo) that
inactivates the transcription factor glioma-associated oncogene family zinc finger-1 (GLI1) [212]. As a result, CYP downregulates the target genes that are responsible for dense
desmoplastic formation. CYP has been shown to inhibit cell proliferation of E3LZ10.7 and
L3.6pl pancreatic cancer cell lines and growth of tumors in mice [213]. Docetaxel (DTX)
acts as a microtubule stabilizer by binding to the β-tubulin and results in mitotic arrest and
subsequent apoptosis. DTX is a second-line therapy for advanced pancreatic cancer
[214]. However, DTX alone is not effective due to chemoresistance. Accordingly, we
hypothesized that a combination of CYP and DTX might have a synergistic therapeutic
efficacy in treating pancreatic cancer. However, both CYP and DTX are hydrophobic drugs
that need an appropriate carrier system to improve their aqueous solubility. One of the
strategies to improve water solubility is to use a co-solvent such as cremophor and Tween
80. The drawbacks of using these chemicals are their severe toxicity such as peripheral
neuropathies, acute hypersensitivity reactions and alteration of pharmacokinetic profiles
[215]. Therefore, polymeric micelle delivery systems, which either physically encapsulate
drugs or conjugate to amphiphilic polymer can overcome these drawbacks. Physical drugencapsulated micelles often have poor drug loading, premature drug release and
unwanted toxicity. In contrast, covalently linked polymer drug conjugate micelles are more
stable in circulation and can release drugs in a controlled manner at the tumor site with a
therapeutically effective concentration [216]. Furthermore, drug conjugation to an
amphiphilic polymer covalently accomplished higher drug payload compared to physically
encapsulated micelles. In addition, the nano-size range confirm accumulation of these
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conjugates in tumor site through the enhanced permeability and retention (EPR) effect
[217].
Previously, we synthesized methoxy poly (ethylene glycol)-block-poly (2-methyl-2carboxyl-propylene carbonate (mPEG-b-PCC) as a polymer delivery system and
conjugated CYP and paclitaxel (PTX) to the carboxyl pendant groups of mPEG-b-PCC
[218, 219]. In the present study, we conjugated CYP and DTX to the carboxyl pendant
groups of mPEG-b-PCC. DTX was used instead of PTX because DTX is more potent than
PTX. The final polymeric conjugates with CYP or DTX contained biocompatible PEG
blocks to contribute stealth property, dodecanol (DC) as lipid chains, and polycarbonate
as the biodegradable backbone. The polycarbonate backbone exhibits low toxicity to
humans because its byproducts are carbon dioxide (CO2) and alcohol. Furthermore, DC
increases the hydrophobicity of the polymer, which promotes self-assembly into nanosized micelles. The polymer drug conjugates were tested for their effect on the proliferation
of MIA-PaCa-2 pancreatic cell lines , which highly express sonic hedgehog (Shh) and Smo
receptor [220]. Finally, this formulation was administered intravenously into mice bearing
orthotopic pancreatic tumors to determine whether P-DTX and P-CYP conjugates inhibit
tumor growth associated with dense desmoplasia.

2.2

Materials and methods
2.2.1

Materials
CYP was purchased from Logan Natural Product (Plano, TX), and DTX was

obtained from LC Laboratories (Woburn, MA). Dodecanol (DC), 1-ethyl-3-(3(dimethylamino)propyl

carbodiimide,

N,N′-dicyclohexylcarbodiimide

(EDC),

N,N-

dimethylpyridin-4-amine (DMAP), N,N′-Dicyclohexylcarbodiimide (DCC), Boc-β-alanine,
dichloromethane (DCM), and hydroxybenzotriazole (HOBT) were obtained from SigmaAldrich (St. Louis, MO). Primary antibodies Shh (rabbit polyclonal antibody sc-9024), Bax
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(rabbit polyclonal antibody sc-6236) and GAPDH (mouse monoclonal antibody sc365062) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). Secondary
antibodies goat anti-rabbit IgG-HRP (sc-2054) and goat anti-mouse IgG-HRP (sc-2055)
were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). Matrigel® matrix
basement membrane was obtained from Corning (Chicago, IL). All other chemicals were
analytical grade and were purchased from Sigma-Aldrich (St. Louis, MO).
2.2.2

Synthesis of mPEG-PCC-g-DTX-g-DC (P-DTX)
Previously, ring opening polymerization was utilized to synthesize monomer 2-

methyl-2-benzyloxycarbonyl-propylene carbonate and its copolymer with mPEG (mPEGb-PBC) followed by reduction to obtain the copolymer containing carboxyl pendent groups
(mPEG-b-PCC) [219]. Carbodiimide coupling reaction was used to conjugate DTX and
DC to the carboxyl groups of mPEG-b-PCC polymer. mPEG-b-PCC (150 mg, 0.0158
mmol) was dissolved in anhydrous dichloromethane (DCM) followed by the addition of
DTX (108 mg, 0.134 mmol), DCC (130 mg, 0.62 mmol) and DMAP (58 mg, 0.48 mmol).
This reaction mixture was stirred for four to five days under nitrogen atmosphere at 4°C.
Then, DC (47 mg, 0.24 mmol) was added, and the reaction was allowed to proceed for
another two days [Figure 2.1A]. The product was purified by precipitation method in
excess cold diethyl ether followed by dialysis against methanol for 4 days using a
regenerated cellulose membrane with 7 K MWCO.
2.2.3

Synthesis of mPEG-b-PCC-g-CYP-g-DC (P-CYP)
Previously, secondary amine terminal was intoduced to CYP structure [218].

Briefly, Boc-β-Ala-TT was synthesized by reacing the following chemicals together. Bocβ-Ala-OH, 2-mercaptothiazoline and DMAP were dissolved in DCM under nitrogen
protection. The solution was first stirred for 5 min −10°C followed by the addition of EDC
and the solution was stirred at −10°C for 3 h and another 14 h at room temperature. After
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reaction, 40 mL DCM was added and the solution was washed with NaHCO3 aq. (0.1 M),
HCl (0.1 M) and then NaCl aq. Then, the organic layer was deried by adding Na2SO4,
and the product was purified by column chromatography (silica gel 60 Å, 200–400 mesh,
EtOAc: CH3OH 15: 1) and then recrystallized from DCM to find yellow powder. The
structure was confirmed by 1H–NMR spectroscopy. Second step is the synthesis of Bocβ-Ala-CYP. Briefly, the final product from the first step (Boc-β-Ala-TT 53 mg 0.185 mmol)
and CYP (38 mg, 0.09 mmol) were dissolved in pyridine under nitrogen. The reaction
mixture was stirred at 50°C for 18 h. The solvent was removed by rotary evaporation. The
resulted product was cleaned by column chromatography (silica gel 60 Å, 70–230 mesh,
EtOAc: Hexane 7:3) to give solid of Boc-β-Ala-CYP in 75% yield. The structure was
confirmed by 1H NMR spectroscopy. Third step is the synthesis of NH2-β-Ala-CYP.
Briefly, the final product from the previuos step (Boc-β-Ala-CYP) was dissolved in
anhydrous DCM (3 mL) and TFA (3 mL) was added at 0 °C. Then, the solvent was
removed by N2 flashing. The crude product was dissolved in chloroform (20 mL) and
washed with aqueous saturated NaHCO3 (3 × 25 mL) and brine (1 × 25 mL). The organic
layer was dried over anhydrous sodium sulfate and filtered. NH2-β-Ala-CYP was obtained
after the solvent was removed by rotary evaporation. The structure was confirmed by 1H
NMR spectroscopy and LC-MS. Final step was to synthesize P-CYP. Briefly, mPEG-PCC
(185 mg, 0.0195 mmol) was dissolved in anhydrous DCM followed by the addition of NH2β-Ala-CYP (75 mg, 0.15 mmol), EDCl (75 mg, 0.375 mmol), HOBt (53 mg, 0.375 mmol).
The reaction was stirred for two days under nitrogen at the room temperature. Then, DC
(72.45 mg, 0.375 mmol) was added and the reaction was allowed to proceed for another
two days [Figure 2.1B]. After completion of the reaction, the final product was purified by
precipitation in large excess of diethyl ether and then by dialysis against ethanol using a
regenerated cellulose membrane of 3500 MWCO.
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Figure 2.1 Synthesis schemes and 1H NMR analysis of polymer-drug
conjugates.
(A) Synthesis scheme of P-DTX, (B) synthesis scheme of P-CYP, (C) 1H NMR
spectrum of P-DTX, and (D) 1H NMR spectrum P-CYP.
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2.2.4

Preparation and characterization of P-CYP and P-DTX micelles
Briefly, 15 mg of P-CYP or P-DTX was dissolved in 500 μL of DCM and the solvent

was removed under reduced pressure to obtain a film, which was vacuum dried overnight.
The film was hydrated by adding one mL of phosphate-buffered saline (PBS; pH 7.4)
followed by probe sonication for 6 min and filtration by using a 0.22 μm filter. A zetasizer
Nano ZS90 (Malvern, Worcestershire, UK) was used to determine the mean particle size
at a scattering angle of 90. Particle size distribution is reported as the mean ± S.D.
2.2.5

Cell Culture
The human pancreatic cancer cell line MIA PaCa-2 was obtained from ATCC

(ATCC® CRL-1420™), and cultured in DMEM medium containing 10% FBS and 1%
penicillin/ streptomycin. Cells were maintained in an incubator with 5% CO2 at 37°C.
2.2.6

Isobologram Analysis
To assess the synergistic effect of combination of P-CYP and P-DTX, dose-

response curves were plotted for the effect of P-CYP and P-DTX on MIA PaCa-2 and
BxPC-3 cell viability separately. Both cells were treated with P-CYP (0,1.5625, 6.25, 25
and 100 μM) and P-DTX (0, 1, 4, 16 and 64 nM) for 48 h. From these curves, The
IC50 values were determine for P-CYP micelles and P-DTX micelles in MIA PaCa-2 and
BxPC-3 cells. Then, Isobologram method of analysis of Steel and Peckham were applied
to check the synergism. The combination index was calculated based on the following
equation

𝑪𝑰 =

𝒅𝟏
𝒅𝟐
+
𝑫𝟓𝟎 𝟏 𝑫𝟓𝟎 𝟐

Where D501 is the dose of P-DTX that produce 50% inhibition effect alone, d1 is
the dose of P-DTX that produce same 50% inhibition effect in combination with P-CYP,
D502 is the dose of P-CYP that produce 50% inhibition effect alone, and d2 is the dose of
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P-CYP that produce same 50% effect inhibition in combination with P-DTX. The
interpretation of CI was done as follow: < 1.0 synergism, =1.0 additive, >1 antagonism.
The parameter d1 was obtained by using constant dose of P-DTX in combination varied
dose of P-CYP (1.5625, 6.25, 25 and 100 μM). The d2 was determine when the dose of
P-CYP combined with d1 produced the 50% inhibition in cell growth.
2.2.7

Cell Viability Assay
To determine the effect of P-CYP micelles, P-DTX micelles and their combination

on cell viability and tumor spheroid formation, MIA PaCa-2 cells were seeded in a 96-well
plate (5000 cells/well) and incubated for 24 h. The culture medium was replaced with
medium containing either empty polymer micelles as a negative control, 25 μM P-CYP
micelles, 16 nM P-DTX micelles, or a mixture of 25 μM P-CYP and 16 nM P-DTX micelles
in 200 μL; cells were then grown for 48 h. Cell viability was evaluated by an MTT assay at
560 nm absorbance and 630 nm for the cell debris. The absorbance results from 630 nm
were deducted from 560 nm to eliminate cells debris effects. The cell viability for all groups
was calculated according to the following formula:
𝐂𝐞𝐥𝐥 𝐯𝐢𝐚𝐛𝐢𝐥𝐢𝐭𝐲 (%) =

𝐚𝐛𝐬𝐨𝐫𝐛𝐚𝐧𝐜𝐞 𝐨𝐟 𝐭𝐞𝐬𝐭 𝐬𝐚𝐦𝐩𝐥𝐞
𝐱 𝟏𝟎𝟎
𝐚𝐛𝐬𝐨𝐫𝐚𝐛𝐧𝐜𝐞 𝐨𝐟 𝐜𝐨𝐧𝐭𝐫𝐨𝐥

For 3D spheroid formation, MIA PaCa-2 cells were seeded in Perfecta3D® 96-Well
Hanging Drop Plates (3D Biomatrix, Inc., Ann Arbor MI) in triplicate and incubated at 37°C,
5% CO2 over the course of time. The cell number per well was 3000 cells in 40 μL of
DMEM. The tumor spheroids were treated with empty polymer micelles as negative
control, 25 μM P-CYP micelles, 16 nM P-DTX micelles, or a combination of 25 μM P-CYP
micelles and 16 nM P-DTX micelles on day 4, 6 and 8 after forming tumor spheroid. The
image under light microscope were taken in the day before starting the treatment, and the
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day after each treatment (day 5th, 7th and 9th) to check the cyctotoxic effect of diferent
formulations on 3D tumor model.
2.2.8

Colony Formation Assay
To evaluate the ability of P-CYP micelles, P-DTX micelles or their combination to

inhibit cells undergoing cell division, MIA PaCA-2 cells were plated in 6-well plate (500
cells/well), and cultured for 24 h to adhere in the bottom of the plate. Thereafter, the
medium was replaced with the medium containing empty micelles as control, 25 μM PCYP micelles, 16 nM P-DTX micelles or a mixture of both conjugates in 2 mL then
incubated for 14 days. Visible colonies, which are consisted of at least 50 cells, were fixed
with 10% formalin and stained with 0.5% crystal violet. All colonies were counted following
the staining, and the percentage of colonies was calculated with respect to the control
colonies as described earlier [221].
2.2.9

Apoptosis Assay
To assess apoptosis, MIA PaCa-2 cells were seeded into 6-well plates (3.5 ×

105 cells/well) and incubated for 24 h. The culture medium was replaced with medium
containing either plain polymer micelles, 25 μM P-CYP micelles, 16 nM P-DTX micelles,
or a mixture of both in 2 mL and incubated for 48 h. Then, the cells were stained with an
Annexin-V and propidium iodide (PI) by using a Vybrant® Apoptosis Assay Kit according
to the manufacture’s protocol (Molecular Probe, Waltham, MA). Apoptotic cells were
quantified by flow cytometry (Becton, Dickison, NJ, USA).
2.2.10 Cell Cycle Analysis
To determine the effect of treatment on cell cycle distribution, 3.5 X 105 MIA PaCa2 cells were plated into 6-well plates with no FBS for 24 h. Cells were then incubated with
empty polymer micelles as a negative control, 25 μM P-CYP micelles, 16 nM P-DTX, or
their mixture in 2 mL for 48 h. Then, cells were detached and fixed in 90% ice-cold ethanol
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overnight. Cells were washed with cold PBS twice and stained with propidium Iodide (PI)
(Molecular Probes, Waltham, MA). Cell cycle analysis was assessed by flow cytometry,
with 10,000 fluorescent events per analysis.
2.2.11 Western Blot Analysis
MIA PaCa-2 cells were seeded in 6-well plates (3.5 X 105 cell/well) for 24 h. Cells
were then treated with various micelles for 48 h. Next, RIPA buffer (Sigma-Aldrich, St.
Louis, MO) was used to lyse the cells, and a bicinchoninic acid (BCA) Protein Assay Kit
(Pierce, Rockford, IL) was used to measure protein concentrations. The lysate was
denatured by heating at 90°C for 5 min, and then subjected to 15% SDS-PAGE.
Thereafter, the lysate was transported to a PVDF membrane using the iBlot™ system
(Invitrogen, Carlsbad, CA). Membranes were blocked with Odyssey® blocking buffer for
1 h at room temperature. Then, membranes were incubated with primary antibodies for
Shh (sc-9024) BAX (sc-6236), and GAPDH (sc-365,062) overnight at 4°C followed by
washing with PBS with 0.05% Tween 20 (PBST). The membranes were then incubated
with their corresponding horseradish peroxidase-conjugated secondary antibodies (sc2055, and sc-2054). Target proteins were detected by ImmunoCruz Western blotting
luminol reagent kit (Santa Cruz Biotechnology, Dallas, TX).
2.2.12 Evaluation in Orthotopic Pancreatic Cancer-Bearing Nsg Mice
All animal experiments were performed according to the NIH animal use
guidelines, and the protocol was approved by the Institutional Animal Care and Use
Committee (IACUC) at the University of Nebraska Medical Center, Omaha, NE. The
orthotopic pancreatic tumor was created in NSG mice 6–8 weeks old by implanting 2 X
106 MIA Paca-2-GFP-luciferase cells into the dorsum of the pancreas using PBS: Matrigel
(1:1 v/v, 50 μL). The tumor size was monitored by noninvasive bioluminescence. In brief,
150 mg/kg of D-luciferin was administered intraperitoneally, and an IVIS imaging system
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(Caliper Life Sciences, Waltham, MA) was used to measure the intensity of
bioluminescence. All animals were then divided randomly into four groups with six animals
in each group once the radiance of the tumor reached 2 X107 p/s/cm2/sr: saline as control,
P-CYP micelles, P-DTX micelles, or a mixture of P-CYP and P-DTX micelles. Those
formulations were given intravenously through the tail vein, 3 times per week for 2 weeks
and the maximum volume injected was 200 μL based on the mouse body weight. Group
1 was injected with saline as the vehicle control. Group 2 received six doses of formulated
P-CYP micelles in 2 weeks, and the equivalent dose of P-CYP was 20 mg/kg of free CYP.
Group 3 received 6 doses of P-DTX micelles in 2 weeks equivalent to 5 mg/kg of free
DTX. Group 4 received a combined-chemotherapy of P-CYP and P-DTX with respect to
their actual therapeutic doses of 5 mg/Kg and 20 mg/Kg P-DTX and P-CYP, respectively.
Bioluminescent radiance of the tumor and body weight were measured every other day
following cells implementation for 45 days. After finishing the study, all animals were
sacrificed, and the tumor and all vital organs (liver, spleen, kidney, heart) were collected
and stored in −80°C.
2.2.13 Immunohistochemical and Immunofluorescences Assay
Tumor tissue was fixed with 10% buffered formalin for 24 h. The samples were
embedded in the paraffin, and thin sections of 4 μm were prepared and immunostained
for cell proliferation marker (Ki-67), apoptosis (cleaved caspase 3), tissue morphology
hematoxylin and eosin (H&E), total collagen (Masson’s trichomes), epithelial–
mesenchymal transition (EMT) modulator (ZEB-1) and metastatic marker (E-cadehrin).
To detect tumor cell apoptosis induced by different micelle formulation, a TUNEL
assay kit (Abcam, Cambridge, MA) was used according to the manufacturer’s protocol. PI
was used to counterstain the tumor sections and then imaged under a fluorescence
microscope(zeiss, Germany).
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2.2.14 Statistical Analysis
Data are represented as the mean ± standard deviation (SD). The statistical
comparisons of the data were performed by student’s t test. P-value <0.05 was
considered statistically significant.

2.3
2.3.1

Results
Synthesis and Characterization of Polymer-Drug Conjugates
P-DTX was synthesized by direct carbodiimide coupling of DTX to one of the

carboxylic acid groups on the hydrophobic block of mPEG-b-PCC copolymer. The
esterification took place favorably at 2′-hydroxyl group due to its less steric hindrance.
In 1H NMR spectra of mPEG-b-PCC, protons corresponding to –CH2 – CH2 – O– of PEG
were observed at δ 3.4–3.6, and –CH2– units of PCC δ 4.2–4.4 and –COOH were
observed at δ 12–14 as reported earlier by our group. After conjugation of DTX to mPEGb-PCC, protons related to DTX were all seen in 1H NMR spectra and DTX content in the
conjugates was determined to be 30.4 ± 3.7% (w/w), as calculated from the peak
intensities of all phenyl proton signals from 7.3 to 8.4 ppm [Figure 2.1 A,C]. Conjugation
of CYP was done through a Boc-b-Ala linker because the secondary amine on CYP was
not easy to conjugate with carboxylic acid group on mPEG-b-PCC. Therefore, after Bocremoval the primary amine on the linker made the conjugation of CYP to the copolymer
much easier. After conjugation of CYP to mPEG-b-PCC, protons corresponding to CYP
were seen in 1H NMR spectra and CYP content in the conjugates were 25 ± 1.6% (w/w)
calculated from proton signal 1.7–2.4 ppm [Figure 2.1 B,D]. P-DTX and P-CYP micelles
were prepared by film hydration method, and the mean particle sizes of P-DTX and PCYP were 66.18 ± 0.4 nm (PDI 0.190) and 73.11 ± 0.7 nm (PDI 0.209), respectively [Figure
2.2]
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Figure 2.2 Particle size distribution of P-CYP and P-DTX micelles using
dynamic light scattering (DLS).
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2.3.2

Combined Treatment with P-CYP and P-DTX Synergistically Inhibits the
Growth of Pancreatic Cancers Cells
To determine whether the combination of P-CYP and P-DTX could have a

synergistic effect, a combination index (CI) was determined after treating 5000 MIA PaCa2 or BxPC-3 cells with P-CYP, P-DTX and combination of P-CYP and P-DTX. MIA PaCa2 and BxPC-3 were treated with P-DTX (0–64 nM) to produce dose-response curves using
MTT assay, with 50% inhibitory concentration (IC50) 39 nM and 34 nM, respectively
[Figure 2.3 A]. In addition, MIA PaCa-2 and BxPC-3 were treated with P-CYP (0–100 μM)
to produce the dose-response curve. Form these curves, the (IC50) were 55 μM and 70
μM, respectively [Figure 2.3B]. The CI was calculated by using this formula: CI =
(d1/D501) + (d2/D502). As shown in Table 2.1, CI value was calculated to be 0.86 and
0.89 when MIA PaCa-2 and BxPC-3 were treated with 25 μM P-CYP and 16 nM P-DTX
combination, respectively.
2.3.3

Combined-Treatment with P-CYP and P-DTX Decreases the Proliferation of
Pancreatic Cancer Cells
Cell viability after incubation of MIA PaCa-2 and BxPC-3 cells with empty micelles,

25 μM P-CYP, 16 nM P-DTX micelles or their combination for 48 h was measured by an
MTT assay. Combination treatment for 48 h reduced MIA PaCa-2 cell viability by 64% and
BxPC-3 cell viability by 60% [Figure 2.4 A]. However, both P-CYP and P-DTX micelles
as monotherapy did not achieve the same level of cell viability reduction when 100 μM PCYP and 64 nM P-DTX were used [Figure 2.3 A,B]. Thus, combination of P-CYP and PDTX micelles had a better effect on decreasing the cell viability of pancreatic cancer cells.
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Figure 2.3 Effect of micelle formulations on pancreatic cancer cells (doseresponse curve).
(A) MIA PaCa-2 and BxPC-3 cells were treated with an increased concentrations
of P-DTX micelles (0-64 nM) for 48h zero is the empty micelles, (B) MIA PaCa-2
and BxPC-3 cells were treated with an increased concentrations of P-CYP
micelles (0-100 µM) for 48h.
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Table 2.1 Synergistic Anticancer Activity of P-CYP and P-DTX in Human
Pancreatic Cancer
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2.3.4

Combined Treatment with P-CYP and P-DTX Reduces Colony Formation
Ability of MIA PaCa-2 Cells
The efficacy of combination treatment with 25 μM P-CYP and 16 nM P-DTX to

inhibit 50 of MIA PaCa-2 cells to come close together and form one colony for 14 days
was evaluated by unaided eye after staining with 0.5% crystal violet. The combination
treatment had more effect on MIA PaC-2 cells in terms of decreasing the percentage of
colonies to 12% compared to 34% and 67% in case of P-DTX micelles and P-CYP,
respectively [Figure 2.4b].
2.3.5

Combination of P-CYP and P-DTX Reduced the Size of MIA PaCa-2 Spheroid
Structure
To simulate the real pancreatic tumor structure, 3D model was performed by using

handing drop method. Combination treatment with 25 μM P-CYP and 16 nM P-DTX had
the smallest spheroid size compared to either P-DTX or P-CYP only [Figure 2.4c].
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Figure 2.4 Cell viability assay at 48 h post-incubation of MIA PaCa-2 and
BxPC-3 cells with a combination of 16 nM P-DTX and 25 μM P-CYP
(a). Colony formation potential of MIA PaCa-2 cells. 500 cells were seeded to 6well plate. After 24 h, formulations were added and at day 14 the colonies were
fixed, stained and counted (b). Treatment of tumor spheroids of MIA PaCa-2 with
the same formulation at days 4, 6 and 8 and images were taken at days 4, 5, 7
and 9 under inverted microscope at 40 x magnification (c). Results are presented
as the mean ± S.D. (n = 5).
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2.3.6

Combined Treatment with P-CYP and P-DTX Enhances Cell Cycle Arrest at
G2/M Phase
The ability of the combination treatment with 25 μM P-CYP and 16 nM P-DTX on

cell cycle arrest was measured by flow cytometry using PI staining. Treatment for 48 h
with the combination of P-CYP and P-DTX increased the fraction of cells in the G2/M
phase compared to that of their monotherapies. The combination treatment resulted in
increased number of cells in G2/M phase from 22.0 ± 0.2% in control to 63.3 ± 2.5%.
However, the increase in the number of cells in the G2/M phase with P-CYP or P-DTX
alone was 30.2 ± 0.2% and 50.9 ± 1.3%, compared to 22.0 ± 0.2% in control respectively
[Figure 2.5a].
2.3.7

Combination of P-CYP and P-DTX Enhances Apoptosis in Pancreatic Cell
Lines
The ability of combined-treatment with 25 μM P-CYP and 16 nM P-DTX to enhance

apoptosis over 48 h was measured by an Annexin V binding assay. Combined-treatment
with P-CYP and P-DTX resulted in more apoptotic cells compared to the single treatments
[Figure 2.5b,c]. The percentage of cell death in the combination treatment group was 64
± 2%, whereas in the case of P-CYP or P-DTX, the percent of cell death was 33 ± 1.5%
and 51 ± 2%, respectively.
2.3.8

Combination Treatment with P-CYP and P-DTX Downregulates Their
Respective Target Proteins
The effect of combination treatment of MIA PaCa-2 cells with 25 μM P-CYP plus

16 nM P-DTX, vs. 25 μM P-CYP or 16 nM P-DTX CYP and DTX alone on their target
proteins, such as Shh and BAX were determined by Western blot analysis at 48 h posttreatment. Combined treatment of P-CYP and P-DTX significantly decreased Shh
expression more than their monotherapies. On the other hand, combined-treatment of PCYP and P-DTX significantly increased BAX expression compared to monotherapies
[Figure 2.5 d].
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Figure 2.5 Cell cycle, apoptosis and Western blot analysis of MIA PaCa-2 cells
after 48 h exposure to empty micelles, 25 μM P-CYP micelles, 16 nM P-DTX
micelles, and their combination.
(a) Cells were grown in 6-well plate (3.5 × 105 cells/well), and cell cycle analysis were
evaluated by flow cytometry after staining with propidium iodide (PI). (b-c) Apoptotic
cells were measured by flow cytometry after staining with Annexin-V and PI. (d) BAX
and SHH protein levels were assessed by Western blot analysis. All data were
presented as the mean ± S.D. (n = 3) (*) P < 0.05, (**) P < 0.001.
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2.3.9

In vivo Evaluation
To investigate the efficacy of combination therapy with P-CYP and P-DTX,

orthotopical pancreatic cancer mouse model was established by implementing stably
luciferase expressing MIA PaCa-2 cells in the pancreas. Once the tumor radiance reached
around 2 X107 p/s/cm2/sr, mice were injected intravenously with the following formulations
via the tail vein thrice a week for 2 weeks: saline, 20 mg/Kg of P-CYP micelles, 5 mg/Kg
of P-DTX micelles, or a mixture of 20 mg/Kg P-CYP and 5 mg/Kg P-DTX micelles. After
12 days of cell implementation in the pancreas, all mice were imaged for luciferase
bioluminescence to determine the tumor growth and divided the mice randomly into
different groups. At day 33, the final bioluminescence images were recorded and showed
significant tumor growth inhibition in mice receiving the combination therapy to monitor the
tumor burden over time [Figure 2.6a]. Luciferase bioluminescence intensity was
measured throughout the study from day 12 to day 33. After plotting the photon intensity
values of different mouse groups versus time, mice administered combination therapy had
the lowest photon intensity value compared to other groups receiving saline, P-CYP
micelles, or P-DTX micelles [ Figure 2.6b]. At the end of the study, all mice were sacrificed
and the tumors and vital organs were collected. Then, the tumor weight and volume were
measured, and we found that mice receiving combination therapy had the lowest tumor
weight (0.23 ± 0.03 g) compared to the mice which were injected with P-DTX micelles
(0.58 ± 0.16 g), P-CYP micelles (0.78 ± 0.10 g), or PBS (1.13 ± 0.04 g) [Figure 2.7A]
Furthermore, the combination therapy had the lowest- tumor volume (202 ± 52 mm3)
compared to P-DTX micelles (661 ± 112 mm3), P-CYP micelles (732 ± 104 mm3), or PBS
(1596 ± 394 mm3) [Figure 2.6c & Figure 2.7B]. To evaluate the general toxicity profile of
the formulation, mouse body weights were monitored throughout the treatment. No
significant differences was observed in body weights in the treatment groups compared to
the control [Figure 2.7C]. In addition, the acute toxicity was evaluated in vital organs (liver,
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spleen, heart, or kidney). There was no huge histological changes post treatment for all
groups [Figure 2.8]
To expound the remarkable effect of combination therapy, immunofluorescence
and immunohistochemistry experiments were carried out. Tumors from mice treated with
combination therapy had loosen groups of epithelial cells; however, mice treated with PCYP micelles or P-DTX micelles had dense epithelial cells. Treatment with combination
of P-CYP and P-DTX had the lowest staining of Ki-67 that reflects the cancer cell
proliferation [Figure 2.9]. Moreover, mice receiving the mixture of P-CYP and P-DTX had
the highest staining of cleaved caspase-3 that reflect the apoptosis of cancer cells [Figure
2.9].
To investigate whether treatment with the combination therapy of P-CYP and PDTX micelles can enhance the ECM degradation, tumor section slides were stained with
Masson’s trichome. Combination treatment with P-CYP and P-DTX micelles degraded the
components of ECM much more efficiently than either P-CYP micelles or P-DTX micelles
alone [Figure 2.10]. An increase in E-cadherin signal was detected in the mice treated
with the combination therapy of P-CYP and P-DTX micelles compared with the control or
monotherapies. Furthermore, ZEB-1, which regulates the EMT was seen in low
expression in mice treated with combination therapy of P-CYP and P-DTX micelles
[Figure 2.10]. TUNEL assay was performed to evaluate the tumor growth inhibition. The
apoptotic cells were stained with green fluorescence. P-CYP micelles or P-DTX micelles
treated group had small number of apoptotic cells, but the combination of P-CYP and PDTX micelles treated group had significant number of apoptotic cells [Figure 2.11].
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Figure 2.6 In vivo efficacy of combined-treatment of P-CYP and P-DTX
after I.V. injection in NSG mouse bearing MIA PaCa-2-GFP-LUC cells
inserted pancreatic tumor
(a) In vivo representative bioluminescence image at last day from mice treated
with free saline (control), P-CYP, P-DTX, and P-CYP + P-DTX. (b) Photon
intensity of orthotopically implanted pancreatic tumor was measured by IVIS
machine at various times post treatment. (c) a representative tumor image after
sacrificing all mice at the end of experiment.
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Figure 2.7 tumor weight and volume at the end of the study, and mice body
weight during treatment
Tumor weight (A) and volume (B) at 3 weeks post treatment. (C) Animal body weight
during the treatment period. Results are presented as the mean ± S.D. for 6 mice per
experimental group (*) P < 0.001 (**) P < 0.0001.
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Figure 2.8 In vivo toxicity assessment.
H & E staining of vital organs, such as liver, spleen, kidney and heart at two weeks after
systemic administration (three times a week for two weeks) of saline as control, P-CYP,
P-DTX and their combination. Scale bar 100 µM.
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Figure 2.9 Immunohistochemical assay-1
Immunohistochemical staining of tumor section for hematoxylin and eosin (H&E), Ki-67
(proliferation related marker), and cleaved caspase-3 (apoptotic marker). The apoptotic
cells are stained brown. Images were taken at 40× magnification.
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Figure 2.10 Immunohistochemical assay-2
Immunohistochemical staining of tumor section with Masson’s Trichome (related to
collagen deposition and desmoplasia), E-cadherin (related to metastasis maker) and
ZEB-1 (EMT modulator)
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Figure 2.11 TUNEL assay of tumor specimens of orthotopic MIA PaCa-2 cells
derived tumor bearing mice treated with P-CYP, P-DTX and their combination
Tumor tissues were fixed, paraffin cryosectioned and immunostained for TUNEL to
detect apoptotic tumor cells. TUNEL positive nuclei (green), DAPI positive nuclei (blue),
scale bar 100 μM.
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2.4

Discussion
PDAC is a highly aggressive cancer usually diagnosed at an advanced state and

poses a medical challenge due to its insensitivity to the majority of chemotherapeutic
agents after long-term treatment. Hh signaling promotes pancreatic cancer cell
proliferation by promoting EMT and decreasing apoptosis by regulation of Bcl-2 and BclX. Hh pathway also promotes cell invasion, migration, and chemoresistance. Therefore,
inhibition of Hh signaling using CYP has the potential to synergistically inhibit tumor growth
and metastasis.
Unlike physically encapsulated drugs into polymeric micelles, which are released
faster due to the dynamic instability of micelles, bioconjugation to amphiphilic polymers
prevents drug release in the circulation and provides sustained drug release. Therefore,
in this study, we conjugated DTX and CYP to a biodegradable amphiphilic diblock
copolymer mPEG-b-PCC with pendant carboxyl acid groups. We previously conjugated a
water soluble drug gemcitabine as well as dodecanol to mPEG-b-PCC, which selfassembled into micelles and showed an enhanced drug delivery to pancreatic tumor,
which resulted in significant reduction in tumor growth [222-224]. In this study, DTX was
conjugated to mPEG-b-PCC through an ester bond at its 2′-OH position. For CYP
conjugation to mPEG-b-PCC, we used a linker containing thiazolidine-2-thione to react
with secondary amine in CYP [218]. The attachment of DC enhanced requisite
hydrophobicity and assisted in the self-assembly of polymer-drug-conjugate micelles.
Combination of P-CYP and P-DTX micelles significantly inhibited MIA PaCa-2 and BxPC3 cell viability [Figure 2.4a]. Isobologram method of analysis of Steel and Peckham
suggests that the combination of P-CYP and P-DTX have a synergistic effect on the
growth inhibition of pancreatic cell lines (MIA PaCa-2 and BxPC-3) since the CI values
were less than one [Table 2.1]. This combination therapy inhibited colony formation,
enhanced apoptosis and cell cycle arrest in G2/M phase, upregulated BAX proteins, and
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downregulated the Shh ligand much more than micelles with either CYP or DTX micelles
alone [Figure 2.4b,c & Figure 2.5].
In vivo efficacy of P-DTX and P-CYP conjugate micelles was determined in
orthotopic pancreatic tumor model developed by MIA PaCa-2-luc-GFP cells in NSG mice.
Promising results were obtained in three treated groups wherein the combination therapy
of P-DTX and P-CYP resulted in a significant reduction in tumor growth rate and tumor
size compared with the control group [Figure 2.6] In addition, the significantly low level of
cellular proliferation and high level of apoptotic cells found in combination group
demonstrated combined P-DTX and P-CYP reduces tumor growth synergistically [Figure
2.9, 2.10 and 2.11]. Furthermore, our formulation carrying P-DTX and P-CYP conjugate
micelles were well tolerated as the vital organs such as livers, spleens, kidneys and hearts
did not show any histological changes after treatments [Figure 2.8]. The tumor tissues of
mice treated with combination therapy were loosened epithelial cells aggregate with a high
amount of interspersed mesenchymal cells, whereas compact epithelial cells were seen
in the control group. Ki-67 is a specific nuclear protein for cancer cell proliferation. Since
the overexpression of this protein is linked to high cancer cell proliferation with low survival
of the patients in many kinds of malignancies such as brain cancer [225]. A low expression
of Ki-67 was seen in mice treated with a mixture of P-CYP and P-DTX mice, indicating low
tumor cell proliferation. Cleaved caspase 3 is a hallmark of programmed cell death. The
expression of this protein after immunostaining was higher in-group treated with
combination of P-CYP and P-DTX micelles compared to other groups. Masson’s trichome
staining method was used to test where this combination has better effect on reducing
ECM deposition. Mice treated with the mixture of P-CYP and P-DTX micelles had lowest
Masson’s trichome staining compared to either control or monotherapies groups. This
finding supports that using combination of P-CYP and P-DTX micelles deceases the stress
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in the cancer microenvironment because of reducing the ECM deposition. Moreover,
measurement of E-cadherin expression of the mice treated with the combination therapy
showed significant enhancement in the expression that explain metastasis to the liver is
low compared to other treated groups. High expression of ZEB-1 was observed in mice
treated with combination of P-CYP and P-DTX micelles compared to either control group
or their monotherapies. The number of apoptotic cells were seen very high in mice treated
with the combination of P-CYP and P-DTX micelles, whereas these cells were found to be
in small number in the control group or monotherapies group. Thus, the possibility to
reduce the proliferation and increase the apoptosis of cancer cells in vitro and in vivo by
using the combination therapy of P-CYP and P-DTX micelles may be a potential
advantage to improve chemotherapy outcomes.
We recently reported higher drug loading and prolonged drug release of P-CYP
and P-PTX conjugate micelles than physically drug encapsulated micelles [218]. In the
present study, we replaced PTX with DTX, since DTX is more potent than PTX [226].
Using CYP as an Hh signaling pathway inhibitor in combination with DTX as a microtubule
stabilizer has the potential to chemosensitize resistant cells and improve the efficacy of
DTX by targeting both desmoplastic cells and bulk tumor cells. In our recent study, CYP
and paclitaxel were conjugated as well as dodecanol to mPEG-b-PCC, and drug release
was in sustained manner. Furthermore, drug loading of PTX and CYP was high and there
their release from the micelles was significantly prolonged, compared to physically drug
encapsulated micelles [218]. Olive et al. showed that the inhibition of Hh signaling pathway
using IPI-926 improved gemcitabine delivery to pancreatic cancer KPC mouse model
[218]. Similarly, the Jiang group demonstrated that CYP disrupts the ECM and enhances
the delivery and efficacy of nanoparticles in pancreatic cancer [41].
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2.5

Conclusion
In conclusion, these studies show that P-CYP and P-DTX combination therapy has

the potential to treat advanced pancreatic cancer associated with dense desmoplasia.
Although tumor regression phenomenon could be achieved by the synergistic effect of
CYP and DTX, the mechanistic regression pathway needs further investigation.
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3.1

Chapter 3. Nanoparticulate Delivery of BRD4/PI3K Dual Inhibitor SF2523 for
Pancreatic Cancer Treatment
Introduction
Delivering of hydrophobic chemotherapeutic agents is a severe issue in the

treatment of the majority of solid tumors, especially pancreatic cancer (PC) because most
of the drugs have a short half-life, drug resistance, and poor cellular uptake due to
desmoplasia [227, 228]. All these factors require drug to be administered in high doses to
be effective, which lead to unacceptable toxicity [229-231]. Moreover, low-water solubility
is an issue and requires co-solvent such as cremophor (CrEL) and Tween 80 should be
used in the formulations. However, including these co-solvents have their own
complications. For instance, commonly administered co-solvents (e.g., cremophor and
Tween 80) with paclitaxel (PTX) are known alter its pharmacokinetic profile and cause
severe toxicity, including hypersensitivity reactions and peripheral neuropathies [232].
Therefore, non-toxic delivery means for lipophilic chemotherapies are urgently needed.
Further, the nature of PC makes the delivery of chemotherapeutic agents nearly
impossible due to the excessive amount of stromal elements (i.e. extracellular matrix
(ECM), fibronectin, and hyaluronans) [233]. Quiescent pancreatic stellate cells (PSCs)
activated by growth factors (e.g.TGF-ß1 and PDGF) and pro-inflammatory cytokines (e.g.
TNFα, IL1, and IL6), are the main source of desmoplasia in the PC [234, 235].
Desmoplasia ultimately leads to the hypovascular microenvironment and resist drug
penetration into the tumor [236]. Moreover, desmoplasia has been shown to induce IFP in
the tumor, which results in low chemotherapeutic uptake and vascular capillary collapse,
and ultimately leads to ineffective chemotherapy. A high IFP leads to reducing molecular
uptake of chemotherapies, and vascular capillaries collapse [237-240]. As a consequence
of desmoplasia, a high IFP has a negative impact on efficacy chemotherapies due to a
lower rate of chemotherapeutic agents’ perfusion[241]. PI3K plays a vital role in the
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desmoplastic formation through the interaction between mitogen and cholecystokinin and
their receptor on stellate cells. This interaction leads to the activation of PI3K signaling
pathway for regulating fibrosis and collagen production [242, 243]. The phosphoinositide
3-kinases (PI3K) signaling pathway is one of the main pathways that is involved in cancer
growth and resistance. PI3K signaling pathway regulates different cellular responses such
as cell proliferation, transformation, motility, and survival of PC cells [67, 68, 244].
Another implicated signaling pathway in PC is Bromodomain and extra-terminal
(BET) motif proteins. BET has a critical role in regulating the transcription of genes that
are involved in tumor growth and fibrosis [245-250]. BET proteins include BRD2, BRD3,
BRD4, and BRDT that bind to acetylated lysine on histone tails and enhance gene
transcriptions during RNA transcription of MYC proteins. It has been shown that using JQ1
as a selective inhibitor of BET protein was beneficial in the regression of solid tumors via
decreasing oncogene c-MYC [246, 251-254]. Another group showed that BRD4 positively
regulates collagen production in primary and immortalized PSCs [255]. Therefore, both
PI3K and BRD4 signaling pathways are implicated in the failure of chemotherapies
because they support tumor growth, desmoplasia formation, and IFP elevation.
SF2523, a small molecule, dual inhibits PI3K, and BRD4 [256]. It has been shown
that SF2325 has a significant high level of inhibition to the PI3K and BRD4 pathways
besides the low toxicity level to the host compared to the combination of the single PI3K
inhibitor and BRD4 inhibitors [256]. Furthermore, SF2523 was shown to be more potent
in inhibiting chondrosarcoma cells and prostate cells than the only BRD4 inhibitor
JQ1[257, 258]; However, SF2523 is a hydrophobic drug that has shorter half-lives due
metabolic instabilities [259].
Given the aforementioned limitations, delivering chemotherapeutic agents in
polymeric nanoparticles (NP) has gained considerable attention for three reasons. NPs
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protect drug molecules from drug metabolism and degradation in the blood [141]. NPs
increase the circulation time of loaded drugs, which could subsequently improve drug
penetration in the tumor and accumulation by the enhanced permeability and retention
(EPR) effect [142, 144-146]. NPs provides low toxic profile due to the sustained release
of drugs [141]. Therefore, we hypothesized that using NP to encapsulate SF2523 could
increase its water solubility, half-life, and delivery to the tumor site.
Previously, we synthesized copolymer mPEG-b-P(CB-co-LA) that formed NPs to
deliver several therapeutic agents for the treatment of metastatic melanoma, prostate
cancer, and liver fibrosis [260-262] Recently, we have also shown that encapsulating
LY293 or QW296 into the [mPEG-b-P(CB-co-LA)] as NP significantly inhibits proliferation
and metastasis of melanoma in the lung metastasis mice model [262]. Therefore, we
prepared SF2523 loaded mPEG-b-P(CB-co-LA) NPs and characterized in vitro. Finally,
SF2523 NPs were injected into tail veins of mice bearing orthotopic pancreatic tumor to
and compared its therapeutic efficacy in inhibiting tumor proliferation, reducing pancreatic
desmoplasia, and lowering IFP compared to free SF2523.

3.2
3.2.1

Materials and methods
Materials
SF2523 was obtained from MedKoo Biosciences, Inc. (Morrisville, NC). Thiazolyl

blue tetrazolium bromide was purchased from CHEM-IMPEX INT’L. (Wood Dale, IL).
FxCycle™ PI/RNase staining solution and penicillin/streptomycin were obtained from
Invitrogen (Waltham, MA). Human microsomes and Dulbecco's modified eagle medium
(DMEM) were purchased from GibcoTM (Waltham, MA). β-nicotinamide adenine
dinucleotide phosphate (NADPH), reduced form, tetra sodium salt trihydrate was
purchased from RPI (Mt. Prospect, IL). Fetal bovine serum (FBS) was bought from Atlanta
Biologicals (Flowery Branch, GA). The PI3-kinase primary antibody ( sc-293115) and p-
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AKT primary antibody were bought from Santa Cruz Biotechnology, Inc.(Dallas, TX). The
c-MYC primary antibody was obtained from Proteintech (Manchester, UK). Collagen-1
(ab-34710), α-SMA (ab5694) and BDR4 (ab128874) primary antibodies were obtained
Abcam (Cambridge, MA). Matrigel® matrix basement membrane was purchased from
Corning (Chicago, IL). All other chemical reagents were of analytical grade and obtained
from Sigma-Aldrich (St. Louis, MO).
3.2.2

Cell culture
The human pancreatic cancer cells MIA PaCa-2 and PANC-1 were purchased

from the American Type Culture Collection (Manassas, VA). These cells were cultured in
DMEM containing 10% FBS and 1% penicillin/streptomycin at 37°C in a humidified
atmosphere containing 5% CO2.
Human pancreatic stellate cells (PSCs), and stellate cell growth medium were
purchased from iXcells Biotechnologies USA, Inc (San Diego, CA). Cells were cultured in
stellate cell growth medium containing 10% FBS and 1% penicillin/streptomycin and
incubated at 37°C in a humidified atmosphere containing 5% CO2. The growth media were
changed every two days.
3.2.3

SF2523 polymeric nanoparticle preparation
In this study, we used our previously synthesized copolymer mPEG-b-P(CB-co-

LA) to prepare SF2523 nanoparticles (SF2325-NP) Polymer was characterized by 1H
NMR to confirm its successful synthesis [260-262]. NPs were formulated using oil/water
(o/w) emulsification in the presence of 1% polyvinyl alcohol (PVA, emulsifier agent).
Briefly, 10 mg of mPEG-b-P(CB-co-LA) and 0.5 mg of SF2523, which is equivalent to 5%
theoretical drug loading, were solubilized in 1 mL of a solvent mixture composed of DCM
and acetone (1:1). Then, 4 mL of 1% PVA solution was added to the mixture containing
mPEG-b-P (CB-co-LA) and SF2523. A probe sonicator (Newtown, CT) was used to
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perform to disperse NP at the following condition; amplitude 20W, pulse on and off time 5
sec, and the duration 5 min. Acetone and DCM were removed using a rotary evaporator.
The aqueous formulation was centrifuged using Sorvall Legend X1 Centrifuge Thermo
Fisher Scientific (Waltham, MA) for 10 min at 5000 rpm to remove unloaded SF2523. The
supernatant was retaken and centrifuged at 24,000 rpm for 30 min to remove 1% of
PVA.The sediments were washed with PBS three times, and re-disperse SF2523-NP in
the desired volume.
3.2.4

Nanoparticle characterization
The particle size distributions of SF2523-NPs was determined using a Malvern

Zetasizer Nano ZS90 ( Worcestershire, UK). The mean particle size was determined at a
scattering angle of 90, and particle size distribution is presented as the average ± S.D
(n=3).
The actual drug loading (w/w) and encapsulation efficiency (EE) were determined
using HPLC using the following conditions; λmax 214 nm using a Inertsil ODS-3 C18 (
250 mm × 4.6 mm, 5 μmm) column (temp 30 °C), mobile phase was mixture of acetonitrile
(ACN) and water (70:30 v/v), injection volume of 20 µL, and flow rate of 1 mL/min. For
determining SF2523 content, 100 µL of SF2523-NP solution was mix with 200 µL of ACN
and mixture was bath sonicated for 5 min at RT followed by centrifugation for 5-10 min at
11,000 rpm. 200 µL of the supernatant was filtered through a 0.2 µm syringe filter
(Acrodisc, Waters, USA) and injected to HPLC.
SF2523 release profile from the formulated nanoparticle was determined using a
dialysis method, and concentration was determined by HPLC using method described
above. In brief, SF2523-NPs (containing 500 µg equivalent of drug) was placed in a
dialysis bag (1,000 MWCO) and suspended into 50 mL of the release medium ( PBS, pH
7.4, 1% Tween 80). The study was performed in a closed chamber orbital shaker at 37°C,
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with a rotation speed of 100 rpm. At regular time intervals (between 0 and 100h), 1 mL
sample was taken and volume was replaced with fresh release medium. Each sample was
mixed with 2 mL of ACN; then bath sonicated for 5 min at RT, centrifuged at 11,000 rpm
for 5-10 min, filtered using 0.2µm filter, and analyzed with HPLC.
3.2.5

SF2523-NP half-life determination
We determined the effect of NP formulation on t1/2 of SF2523 in presence of human

liver microsomes SF2523 content in the samples was quantified using LC-MS/MS. The
SF2523-free and SF2523-NP were incubated with the reaction media composed of human
liver microsomes (HLM, 1 mg/mL), 40 mM MgCl2, 1.0 mM NADPH, and phosphate buffer
(100 mM, pH 7.4) to make the final concentration of 1 µM. The samples (100 µL) were
taken at 0-60 min for SF2523-Free, and at 0-180 min for SF2523-NP. All samples were
mixed with 300 ACN in a 1.5 mL centrifuge tube, centrifuged at 12,000 for 15 min. Then,
150 µL of the supernatant was filtered and transferred into HPLC via to be analyzed by
LC-MS/MS. Based on the area under the curve, the percentage of SF2523 remaining was
quantified each time points and transformed into natural log values(Y-axis) and plotted
against time (X-axis).
3.2.6

Cell viability study
To determine the effect SF2523-Free and SF2523-NP on cell viability, MIA PaCa-

2 cells or PANC-1 cells were seeded in a 96-well plate (4000 cells/well) and incubated for
24 h. The culture medium was replaced with 200 µL of growth medium containing either
2 µL of DMSO, 0.1, 1, 5, 10, 25, and 50 µM of SF2523-Free, or empty NP, 0.1, 1, 5, 10,
25, and 50 µM of SF2523-NP. The cell viability assays were performed in both cell lines
at different time point 24, 48, and 72h. At each time point, 25µL of 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) solution in PBS were added to cells.
and incubated for 4 h at 37 °C. The growth media and MTT solution were aspirated after

64
centrifugation (1,500 rpm for 2 min) to help formazan crystal to sediment. The formazan
crystals were solubilized in 100 µL of the DMSO. The formazan absorbance corresponding
to viable cells was measured at 560 nm and subtracted from absorbance of cell debris at
630 nm. The cell viability of SF2523-Free and SF2523-NP at 48h was calculated based
on the following equation.

𝐶𝑒𝑙𝑙 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 (%) =

𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑆𝐹2523
𝑥 100
𝑎𝑏𝑠𝑜𝑟𝑎𝑏𝑛𝑐𝑒 𝑜𝑓 𝐷𝑀𝑆𝑂

The IC50 for both SF2523-Free and SF2523-NP were plotted after transforming the
concentration into log value for accurate IC50.
3.2.7

Cellular uptake analysis
The cellular uptake efficiency study was determined using the flow cytometry [263].

In brief, MIA PaCa-2 cells (0.3 X 106) were seeded in 6-well plates and in incubated for
24h. Then, MIA PaCa-2 cells were treated with 2 mL of freshly prepared cultured medium
containing coumarin-6, a free drug (coumarin-6-Free), and coumarin-6 loaded
nanoparticles (coumarin-6-NP) equivalent to 30 µg/mL for both of them and incubated for
2 hours in incubator. As a negative control, cells were treated only culture media. After 2
hours, cells were washed three times with cold PBS, trypsinized, centrifuged at 1000 rpm
for three mins, and rewashed once again before going to FACS analysis. The free particles
and cell debris were excluded via setting the gate on the plot of the side-scattered light
(SSC) versus forward-scattered light (FSC). A total of 10,000 events were analyzed. An
increase of fluorescent intensity in cells treated with coumarin-6-Free and coumarin-6-NP
compared to that in negative control was expressed as median fluorescence intensity
compared to negative control.

65
3.2.8

Cell cycle analysis
To determine the effect SF2523-NP on cell cycle distribution, MIA PaCa-2 cells

(3.5 X 105 cells/well) were plated in the 6-well plate for 24h with no FBS. Then, the cells
were treated with empty NP, 5 µM SF2523-NP, and 10 µM SF2523-NP for 48h. Cells were
trypsinized and fixed in ice-cold ethanol (70%) overnight. Cells were washed twice with
ice-cold PBS, stained with FxCycle™ PI/RNase solution for 15 min at RT in the dark
according to the manufacturer’s protocol. Cell cycle distributions were assessed by a flow
cytometer (BD FACS Calibur, NJ) with 10,000 fluorescent events per assessment.
3.2.9

Colony formation assay
To evaluate the ability of SF2523-NP to inhibit colony formation capability of MIA

PaCa-2 cells, cells were plated in the 6-well plate (500 cells/well), and cultured for 24 h to
adhere to the bottom of the plate. Next, the medium was replaced with the medium
containing empty NP, 5 µM SF2523-NP, and 10 µM SF2523-NP in 2 mL then incubated
for 14 days. A single colony consists of at least 50 cells, were fixed with 4%
paraformaldehyde, washed with ice-cold PBS twice, stained with 0.5% crystal violet, and
washed with ice-cold PBS thrice. Colonies were counted manually, averaged, and
calculated the percentage of colonies with respect to the controlled group colonies as
described previously[221].
3.2.10 In vivo evaluation of SF2523-NP in orthotopic pancreatic cancer-bearing
NSG mice
All in vivo experiments were performed according to the NIH animal use
regulations and protocol approved by the Institutional Animal Care and Use Committee
(IACUC) at the University of Nebraska Medical Center (UNMC), Omaha, NE. The NSG
mice (6-8 weeks old) were used to establish the desmoplastic orthotopic pancreatic tumor
according to our established method [264]. In brief, stable luciferase expressing MIA Paca2-GFP-luciferase positive cells and human pancreatic stellate cells (hPSCs) were mixed
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at a 1:1 ratio in Matrigel (1:1 v/v, 50µL) and implanted into the dorsum of the pancreas
using PBS. The tumor growth was monitored via bioluminescence measurement using
IVIS. Briefly, D-luciferin (150 mg/kg) was injected in the peritoneum cavity of the mice, and
then an IVIS imaging machine (Caliper Life Sciences, Waltham, MA) was used to quantify
the intensity of bioluminescence. Once the intensity of the bioluminescence in tumors
reached 1.5 X 107 p/s/cm2/sr, mice were divided randomly into three groups, empty NP
control, SF2523-Free, and SF2523-NP. Both SF2523-Free and SF2523-NP were
administered as I.V. through tail vein injection. Each mouse received six doses, through
two weeks (3 doses per week). The maximum volume of the injection was 200 µL.
SF2523-Free group was injected with SF2523 at the dose of 30 mg/kg dissolved in 35%
of co-solvent (30% Cremophor® EL, 20% ethanol & 50% propylene glycol) in addition to
65% of dextrose solution. SF2523-NP group was injected 30 mg/kg equivalent to free
drug. The bioluminescent intensity and mice’s body weight were monitored every other
day after start of the treatments. At day 30, the terminal experiment was performed to
measure the interstitial fluid pressure (IFP). Then, mice were sacrificed, tumor and other
vital organs such as liver, spleen, kidney, and heart were collected for other experiments.
3.2.11 Interstitial fluid pressure (IFP) measurement
IFP was measured on the last day of the experiment using a Millar Mikro-Tip®
pressure catheter transducer (SPR-1000, 0.33 mm diameter) with a dynamic pressure
range from −50 to 300 mmHg, possessing a shielded side-mounted sensor. The catheter
was linked to the pressure control unit (PCU-2000), and ADInstruments PowerLab® data
acquisition system (Millar Instruments, Inc.) [237, 265, 266]. LabChart software was used
to record and analyze the data. Before each measurement, the recording system was
calibrated to 0, 25, and 100 mmHg according to manufacture’s protocol. In brief, All mice
were anesthetized by using Isoflurane, and then the abdominal cut was performed to make
the pancreas ready for measuring the IFP. The 25 gauge needle with around double the
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diameter of the probe, was introduced first into the pancreatic tumor. Thereafter, the probe
was inserted into the same space after removing the needle.
3.2.12 Immunohistochemical assay
After collecting the tumor and other vital tissues, a small piece from each tissue
was taken and fixed with 10% buffered formalin for 24 h. All tissues were embedded in
the paraffin. A thin section (4 μm) of each tissue was sliced to perform
immunohistochemical experiments; histology (hematoxylin and eosin, H&E) apoptotic
cells ( cleaved caspase 3) (1:200 dilution), and proliferative cells (Ki-67) (1:200 dilution).
Moreover, immunohistochemistry staining was used to test the effect of SF2523-Free and
SF2523-NP on its target proteins, including BDR4 (1:50 dilution), c-MYC (1:100 dilution),
PI3K (1:100 dilution), p-AKT (1:500 dilution), α-SMA (1:500 dilution), collagen-1 (1:500
dilution), HIF-1α (1:100 dilution). The signals were quantified using Definiens Tissue
Studio dual software.
3.2.13 Statistical analysis
Data were represented as average ± S.D. (n=3) Two-tailed Student's t-test was
utilized for comparison between two groups. *P <0.05 and #P <0.01 were considered as
statistical significance.

3.3
3.3.1

Results
Preparation and characterization of SF2523-NP
The polymer used for preparing NPs was mPEG-b-P(CB-co-LA). This polymer was

synthesized and characterized according to previously reported methods [260-262]. NPs
were successfully prepared by emulsion solvent evaporation method [267]. The
encapsulation efficiency (EE) for 2.5%, 5%, and 7.5% of theoretical SF2523 loading was
found to be 81 ± 9.4, 82.15 ± 3.8 and 60.41 ± 4.38, respectively [Table 3.1]. The average
particle size of SF2523-NP was 162.1 ± 10.3 nm based on DLS characterization [Figure
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3.1A]. The in vitro drug release was sustained and only 63 ± 12.3 % of SF2523 was
release over 96 hours at 7.4 pH, as shown in figure 3.1B.
3.3.2

SF2523-NP microsomal stability and half-life determination
To determine the effect of SF2523-NP on its metabolic stability, SF2523-Free and

SF2523-NP were incubated in HLM for up to 180 min. The amount of SF2523 depleted
after 60 min incubation in HLM was 4.5% for SF2523-Free versus 36.6% for SF2523-NP
as determined by LC-MS/MS [Figure 3.2A]. Under the same condition, the metabolic rate
constant was 0.0504 fraction/ min for SF253-DMSO; however; It was 0.0105 fractions/min
for SF2523-NP. The half-life of SF2523-Free was 14 min, whereas it was 67 min SF2523NP [Figure 3.2B].
3.3.3

SF2523-NP Inhibit the growth of pancreatic cancer cells in a dose-dependent
manner
We determined the growth inhibitory activities of SF2523-Free and SF2523-NP in

pancreatic cancer cell lines MIA PaCa-2 and PANC-1. A dose-response curve was
determined after treating cells with SF2523-Free (0.1- 50 µM) or SF2523-NP (0.1, - 50
µM) for 48 h. Both SF2523-Free and SF2523-NP
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Table 3.1 Determination of drug loading and encapsulation efficiency of SF2523NP
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Figure 3.1 Polymeric nanoparticles characterization.
The particle size distribution of SF2523-NP was measured using dynamic light
scattering (DLS), (B) the release of SF2523 from nanoparticles at pH7.4, The
amount of released drug were quantified using HPLC after establishing standard
curve for SF2523.
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Figure 3.2Metabolic stability of SF2523-NP and SF2523-Free in human liver
microsomes (HLM).
(A) Time-dependent depletion of SF2523 by NADH*-supplemented HLM. The data are
expressed as percentage of SF2523 remaining at each time compared with time 0 min
and represent the mean ± SD (n=3). (B) The metabolic rate constant (-k) and t1/2 of
SF2523-Free and SF2523-NP.
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decreased the percentage of PC cell viability in a dose-dependent manner as shown in
figure 3.3 A&B. However, SF2523-NPs showed significant higher cytotoxicity than free
drugs in MIA PaCa-2 cells with IC50 of 5.22 µM Vs. 9.16 µM respectively in 48h. However,
IC 50 of SF2523-Free (4.9 µM) and SF2523 NPs (5.60 µM) were not significantly different
in PANC-1 cells after 48h of treatment.
3.3.4

Coumarin-6-NP had high cellular uptake by MIA PaCa-2 cells.
To determine whether coumarin-6-NP or coumarin-6-Free have higher cellular

uptake, the median fluorescent intensity was measured using flow cytometry. As shown
in figure 3.3C, the median fluorescent intensity in coumarin-6-NP (2978 ± 61.54 MFI) was
significantly higher than that of the coumarin-6-Free (1039.67 ± 60.93 MFI) treated group.
3.3.5

Treatment with SF2523-NP Enhances Cell Cycle Arrest at G0/G1 phase
The capability of SF2523-NP (5 µM & 10 µM) to cause cell cycle arrest was

evaluated after treatment for 48h using Flow Cytometry. Treatment of MIA PaCa-2 cells
with 5 µM SF2523-NP significantly increased the percentage of cells in G0/G1 from 55.71
± 0.09% in empty-NP to 71.47 ± 0.27% and 10 µM SF2523-NP significantly increased the
percentage of cells in G0/G1 from 55.71 ± 0.09% in empty-NP to 75.69 ± 0.42% [Figure
3.4].
3.3.6

Treatment with SF2523-NP Decreases Colony Formation Ability of MIA PaCa2 cells
The efficacy of 5 µM and 10 µM SF2523-NP to inhibit 50 singlet cells of MIA PaCa-

2 from forming a single colony by coming close to each other was assessed by using
colony formation assay. The number of colonies was evaluated via unaided eye right after
staining with crystal violet (0.5%). SF2523-NP (5 µM) decreased the percentage of MIA
PaCa-2 colonies to 49 ± 3.26%, and SF2523-NP (10 µM) reduced the percentage MIA
PaCa-2 colonies to 34 ± 2.49% [Figure 3.5].
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Figure 3.3 Effect of SF2523-Free or SF2523-NP on cell viability and cellular
uptake.
(A&B) Cells viability assessment in MIA PaCa-2 or PANC-1 cells treated with SF2523Free and SF2523-NP after 48h of treatment. All treatments were performed in triplicate
(n=3), and data were presented as average ± S.D. (C) Intracellular uptake of analysis
of coumarin-Free and coumarin-NP in MIA PaCa-2 cells through flow cytometry.
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Figure 3.4 The effect of SF2523-NP on cell cycle distribution.
Cell cycle distributions were analyzed by flow cytometry after staining with PI. All data
were presented as the average ± S.D (n=3) (*) P<0.05.
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3.3.7

SF2523-NP inhibits tumor growth in an orthotopic pancreatic cancer mouse
model
To investigate the efficacy of SF2523-NP, an orthotopic pancreatic cancer mouse

model was created via injecting MIA PaCa-2 cells expressing stable luciferase and human
pancreatic stellate cells (hPSCs) in 1:1 ratio. When the tumor bioluminescence intensity
reached 1.0 X 107 p/s/cm2/sr. Mice were randomly divided into three groups, and injected
the following different treatments: empty-NP, SF2523-Free, (30 mg/kg) or SF2523-NPs
(30 mg/kg). All the formulations were administered intravenously through tail vein injection
three times a week for two weeks. Both the treatments; SF2523-Free and SF2523-NP
showed inhibition of tumor growth, however SF2523-NP showed higher tumor growth
inhibition as determined by IVIS imaging [Figure 3.6A]. The quantitation the
bioluminescence photon intensity readings values (p/s/cm2/sr) of different mouse groups
versus time (days) showed that SF2523-NP treated group had significantly low
bioluminescence photon intensity value compared to control or SF2523-Free groups
[Figure 3.6B] Accordingly, SF2523-NP treated group had the lowest tumor weight (0.30
± 0.03 g) compared to control ( 1.42 ± 0.27 g) or SF2523-Free group (0.52 ± 0.09), and
SF2523-NP treated group had the lowest tumor volume compared to either control or
SF2523-Free groups [Figure 3.6C- D]. The general toxicity of all formulations was
assessed by monitoring mice’s body weight during treatment. There was no more than
5% reduction in mice’s body weight in control, SF2523-Free, and SF2523-NP compared
mice's body weight before starting treatments [Figure 3.7A].
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Figure 3.5 The potential of MIA PaCa-2 cell to form colonies after treating
SF2523-NP (5 µM) and SF2523-NP (10 µM).
500 cells were plated in a 6-well plate for 24h. Then, empty NP 5 & 10 µM SF2523-NP
were added for 14 days. The formed colonies were fixed, stained and counted (A).
Comparative analysis of colony formation percentages. This experiment was carried out
in triplicate (n = 3). The data is presented as average ± S.D. (B) A representative
pictures of empty-NP, SF2523-NP (5 µM) and SF2523-NP (10 µM) (*) P<0.05
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Figure 3.6 The therapeutic effect of SF2523-Free (30 mg/Kg) versus SF2523-NP
(30 mg/Kg) in orthotopic pancreatic tumor-bearing NSG mice.
(A) A representative bioluminescence image at the end of the treatment. (B)
Quantitation of photon intensity of tumor at different time points during treatment. (C)
The tumor weight from different treatment groups. (D) An illustrative tumor picture from
different groups. The data were represented as average ± S.D (n=5), *P < 0.05
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3.3.8

SF2523-NP restores the IFP in an orthotopic pancreatic cancer mouse model
On the last day of in vivo experiments, and under anesthesia, mice in different

groups were used to measure IFP. The IFP was significantly lower (50.60 ± 3.71 mmHg)
in SF2523-NP treated mice compare to SF2523-Free treated mice (110.96 ± 38.05
mmHg). The control group had the highest IFP (132.84 ± 32.50 mmHg) among these
[Figure 3.7B]. Furthermore, there was no significant change in the histology of vital
organs including the liver, spleen, heart, or kidney [Figure 3.8].
Immunohistochemistry experiments were further performed to evaluate the effect of
SF2523-NP on cancer-related markers. SF253-NP significantly decreased the percent of
Ki-67 positive cells (53.98 ± 9.57%) compare to either SF2523-Free (70.88 ± 6.33%) or
control groups (74.69 ± 5.24) [Figure 3.9]. The Ki-67 staining reflects that the SF2523-NP
inhibited the cancer cell proliferation more effectively. Additionally, SF2523-NP
significantly increased the percentage of the cleaved caspase-3 positive area (11.51 ±
2.82%) compared to for SF2523- Free (4.99 ± 1.19%) group, and (1.63 ± 0.39%) for the
control group [Figure 3.9]. The cleaved caspase-3 staining represents the apoptotic cells
in the tumor tissue section.

79

Figure 3.7 The body weight of mice were taken at the day of the first treatment
and during the treatments and Interstitial fluid pressure measurement
Data were presented as the average ± S.D. Number of mice per group was 5 mice each
group (n = 5, *P < 0.05) (B) Assessment of intra-tumoral interstitial fluid pressure (IFP).
After the end of treatments, the IFP was measured using a Millar Mikro-Tip® pressure
catheter transducer (SPR-1000, 0.33 mm diameter) with a dynamic pressure range from
−50 to 300 mmHg. SF2523-NP treatment significantly reduced the IFP compared to SF2523-Free treatment.(*P < 0.05, n=5)
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Figure 3.8 In vivo SF2523-NP toxicity assessment
The H&E staining of vital organs, such as heart, lung, liver, spleen, and kidney after
treatment with empty-NP, SF2523-Free and SF2523-NP.Scale bar 50 µM.
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Figure 3.9 Immunohistochemical staining of tumor sections for proliferation and
apoptotic markers.
(A) Stains of tumor sections for the cell proliferation marker Ki-67. (B) Quantification of
Ki-67-positive cells in the tumor sections. (C) Stains of tumor sections for cleaved
caspase-3. (D) Quantification of the cleaved caspase-3-positive area in the tumor
sections. The representative images were taken at 10X magnification and 40X for image
with the red edges. (*) P < 0.05
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To assess whether SF2523-NP has an inhibitory effect on BDR4/Pi3K pathways,
tumor tissue sections were immunostained for the respective proteins including BDR4, cMYC, PI3K, and p–AKT. SF2523-NP significantly reduced the percentage of BDR4
positive cells ( 25.0 ± 5.0%) more than SF2523-Free (36.86 ± 3.0%), or control group
(43.17 ± 5.0%), and significantly decreased the percentage of c-MYC positive cells (41.42
± 3.85%) whereas the percentage of c-MYC positive cell was 49.36 ± 2.53% in SF2523Free group and 63.79 ± 10.84% in control group [Figure 3.10]. Moreover, SF2523-NP
showed a greater reduction of percentage of PI3K positive (9.21 ± 1.21%) and p-AKT (
8.16 ± 1.25%) either compare to SF2523-Free group ( 26.63 ± 3.42% for Pi3K and 14.41
± 4.71%) or control group ( 28.78 ± 6.73% for Pi3K and 19.63 ± 3.07% for p-AKT) [Figure
3.11].
In addition, desmoplasia markers including α-SMA and Collagen-1 were
immunostained with the respected primary antibodies, and it was found that SF2523-NP
reduced the percentage of α-SMA positive area (26.96 ± 1.31%); compared to (34.91 ±
1.95%) for SF2523-Free group and (41.53 ± 2.97%) for control group [Figure 3.12]
SF2523-NP decreased the percentage of the collagen-1 positive area (6.51 ± 0.92%)
whereas in SF2523-Free or control groups the percentage of the collagen-1 positive was
(8.55 ± 0.79%) and
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Figure 3.10 Immunohistochemical staining of tumor sections for BDR4 and cMYC proteins marker.
(A) Stains of tumor sections for the BDR4 proteins marker. (B) Quantification of BDR4
positive cells in the tumor sections. (C) Stains of tumor sections c-MYC proteins marker.
(D) Quantification of c-MYC positive cells in the tumor sections. The representative
images were taken at 10X magnification and 40X for image with the red edges. All
sections were quantified using Definiens Tissue Studio software. (*) P < 0.05
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Figure 3.11 Immunohistochemical staining of tumor sections for PI3K and P-AKT
proteins marker.
(A) Stains of tumor sections for the PI3Kproteins marker. (B) Quantification of PI3K
positive cells in the tumor sections. (C) Stains of tumor sections p-AKT proteins marker.
(D) Quantification of pAKT positive cells in the tumor sections. The representative
images were taken at 10X magnification and 40X for image with the red edges. All
sections were quantified using Definiens Tissue Studio software. (*) P < 0.05
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Figure 3.12 Immunohistochemical staining of tumor sections for Collagen-1 and
α-SMA marker.
(A) Stains of tumor sections for desmoplasia marker collagen-1. (B) Quantification of
collagen-1 positive area in the tumor sections. (C) Stains of tumor sections α-SMA
marker. (D) Quantification of the α-SMA positive area in the tumor sections. The
representative images were taken at 10X magnification and 40X for image with the red
edges. All sections were quantified using Definiens Tissue Studio software. (*) P < 0.05
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(16.34.82 ± 2.89%), respectively [Figure 3.12] . Moreover, The percentage of HIF-1a
positive cells was significantly the lowest in SF2523-NP group (22.35 ± 6.05%) either
compared to SF2523-Free group (36.38 ± 3.61%) or control group (39.88 ± 2.58%)
[Figure 3.13].

3.4

Discussion
PC is a lethal malignancy with a 5-year survival rate of less than 8-10%, and

survival time no more than six months [268, 269]. The absence of specific indications and
symptoms similarities with other pancreatic diseases makes early diagnosis nearly
impossible [270]. Many factors including genetic alterations, desmoplasia formation, and
high interstitial fluid pressure lead to poor prognosis of PC patients. Another issue with PC
treatments is ineffective drug delivery due to the short half-life of small drugs, low-water
solubility, low drug penetration, and antagonistic effect of extensive co-solvents [271].
Both PI3K and BDR4 promote PC cell proliferation, regulate anti-apoptotic proteins,
support the formation of desmoplasia that ultimately leads to elevate the IFP of tumor and
treatment failure. Furthermore, It has been shown that c-MYC, which is downstream signal
in BDR4 pathway, and PI3K are involved in development of chemoresistance [272-274].
Therefore, inhibiting these pathways using SF2523 a BDR4/PI3K inhibitor has the
potential to improve efficacy through inhibiting tumor growth, reducing desmoplasia, and
lowering IFP. However, SF2523 has low water-solubility, and short half-life, making it
unfavorable for in vivo treatment. To improve these issues, NP approach is an excellent
option because NP provides
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Figure 3.13 Immunohistochemical staining of tumor sections for HIF-1a marker
Stains of tumor sections for hypoxia marker HIF-1a. (B) Quantification of HIF-1 positive
cells in the tumor sections. The representative images were taken at 10X magnification
and 40X for the image with the red edges. All sections were quantified using Definiens
Tissue Studio software. (*) P < 0.05
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many advantages including protecting drug from metabolism and degradation, increasing
water-solubility and circulation time of encapsulating drugs, improving drug delivery
through enhanced permeability and retention (EPR) effect, providing better toxic profile
compare to co-solvents such as CrEL.
In this study, our approach was to load SF2523 into NPs using mPEG-b-P(CB-coLA) copolymer. This approach has two benefits. First, the NP formation allows to increase
the SF2523 stability and to be delivered through intravenous injection. Seconds, the
hydrophilic part of mPEG part of the polymer prevent aggregation of NPs, and reduce
possible uptake by the reticuloendothelial system (RES), and thus increases their
circulation times in the blood. We expected these attribution will ultimately contribute to
enhance the therapeutic effect of SF2523-NP compared to SF2523 as a free drug .
SF2523-NPs were stable at 25 oC for one week with no precipitation of drug and no
significant change in average particle size. These observations suggest that S2523-NP
have a good stability profile at room temperature. NPs could load 5% w/w of drug with
82.15 ± 3.8 encapsulation efficiency and showed release of around 60% over three days
[Figure 3.1B]. Moreover, NPs preserved loaded SF2523 from being metabolized by the
liver enzyme and increased its half-life five folds as compared to SF2523 as free drug. .
This finding are in line with reports from other groups. They have shown that polymeric
NPs offered metabolic protection for lopinavir against liver microsomes [275]. SF2523-NP
inhibited MIA PaCa-2 PANC-1 cell viability in dose-dependent manner and decreased the
IC50 compared to SF253-Free. This could be due to the higher cellular uptake of SF2523NP showed compared to SF2523-Free [Figure 3.3C] [275-277]. SF2523-NP showed
significant increased cell cycle arrest at the G0/G1 phase. SF2523-NP significantly
inhibited colony formation [Figure 3.4]. This result is in line with literature. Inhibition of
BDR4/MYC pathway induce cell cycle arrest at G0/G1 phase, and suppress the colony
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formation [278]. These in-vitro data suggested that SF2523-NP could be an attractive in
vivo therapeutic approach.
In vivo efficacy assessment of SF2523-NP was evaluated in orthotopic
desmoplastic pancreatic tumor-bearing mice. The model was generated by injecting a
mixture of MIA PaCa-2-luc-GFP and PSC cells in the tip of pacrease in NSG mice. At the
dose of 20 mg/kg, SF2523 was well tolerated by mice without any signs of toxicity (weight
loss, activities, or eating/drinking habits). Mice treated with SF2523-NP showed a
signification reduction in tumor size and tumor growth rate compared to either SF2523Free or control groups [Figure 3.6].These promising findings could be explained by the
significant drop in Ki-67 expression in mice treated SF2523-NP compared to mice treated
with SF2523-Free [Figure 3.9]. The Ki-67 is involved in ribosomal RNA transcription and
synthesis therapy. It is necessary for cellular proliferation and is also associated with a
high survival rate of different kinds of tumors [225]. Moreover, we observed a significant
increase in cleaved caspase-3 staining representing higher level of programmed cell death
by apoptosis in tumor sections of mice treated with SF2523-NP compared to mice treated
with SF2523- Free [Figure 3.9].
Further, the dual inhibitory effect of SF2523-NP on BDR4/PI3K pathway was
determined using IHC staining. The significant reduction in the percentage of BDR4 and
c-MYC positive cells was seen in tumor sections of mice treated with SF2523-NP
compared to tumor section of mice treated with SF2523-Free [Figure 3.10]. There was a
significant reduction in the percent of positive cells of PI3K and p-AKT in tumor section of
mice treated with SF2523-NP compared to tumor section of mice treated with S2523-Free
[Figure 3.11]. Moreover, the collagen-1 and α-SMA immunostaining experiments were
performed to check where SF2523-NP has a superior effect on reducing desmoplasia
component [Figure 3.12]. It has been reported that interaction between mitogen and
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cholecystokinin and their receptor on PSC leads to the activation of PI3K signaling
pathway that regulates fibrosis and collagen production[242]. Furthermore, another group
showed that different BET proteins have different roles in collagen production; however,
BRD4 positively regulates collagen production in primary and immortalized PSCs [255]
Additionally, it has been shown that desmoplasia plays a vital role in creating
hypoxic

microenvironment,

which

supports

tumor

progression,

and

limits

chemotherapeutic agents delivery by activating the hypoxia-inducible factor-1a (HIF-1a)
[279]. The percentage of HIF-1a positive cells in mice treated with SF2523-NP was
significantly lower than other treated groups [Figure 3.13]. Many reports showed that
pancreatic desmoplasia increases IFP therapy decreases the effectiveness of
chemotherapies [241, 280-282]. Measurement of IFP of mice treated with SF2523-NP
showed a significant reduction in the internal pressure of pancreas compared either
SF2523-Free or control groups [Figure 3.7B]. These findings further highlight that
SF2523-NP is more effective than other groups in decreasing desmoplasia component
and IFP.

3.5

Conclusion
We have formulated SF2523, which is a dual inhibitor of BDR4/PI3K SF2523

polymeric NPs. These NPs successfully delivered SF2523 to tumor site through EPR
effect and released in the sustained pattern, leading to high effect on inhibition of
downstream pathway of BDR4/PI3K, reduction of desmoplasia component, and reduction
of IFP. Therefore, SF2523-NP shows a high tumor inhibition compared to SF2523-Free.
In future studies, SF2523-NP will be combined with other chemotherapies to improve their
efficacy.
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4.1

Chapter 4. Summary and Future Directions
Summary
The treatment of PDAC is still a challenge due to the difficulty of being diagnosed in

the early stages and development of resistance to standard chemotherapies. Desmoplasia
induces the chemoresistance in PDAC. There are many signaling pathways, which
support and induce the formation desmoplasia. The Hh, PI3K, and BDR4 signaling
pathways involved in supporting, developing desmoplasia, and pancreatic cancer
progression. We used different strategies to overcome these challenges. In chapter one,
The strategy was to combine to microtubules stabilizer (DTX) and Hh signaling pathway
inhibitor (CYP) to overcome chemoresistance and improve the therapeutic effect.
However, Both DTX and CYP are hydrophobic. Therefore, they need an appropriate
delivery system to enhance their water solubilities, therapy improves therapeutic efficacy.
Our approach was to synthesize PEG-based polymeric drug conjugate micelles. These
polymeric-drug conjugate (P-DTX and P-CYP) can assemble into the micelles of less than
100 nm with drug loading more than 20% w/w. These combination micelles inhibited the
tumor growth effectively when introduced into NSG mice bearing created orthotopically
using MIA PaCa-2 cells compared to monotherapy micelles.
SF2523 is a dual inhibitor for PI3K/BDR4 pathways. These pathways play a crucial
role in pancreatic cancer progression and resistance development by supporting
pancreatic desmoplasia. The hydrophobicity of SF2523 had to use the toxic co-solvents
to make it appropriate for systemic therapy. Our approach to improving the water solubility
without using toxic co-solvents was to synthesize a biodegradable polymer with polyester
and polycarbonate hydrophobic core. Methoxy polyethylene glycol-b-poly (carbonate-colactide) (mPEG-b-P(CB-co-LA)) was synthesized to encapsulate SF2523 in the
polycarbonate hydrophobic core of the Biodegradable polymer. SF2523 was loading into
the polymer using o/w emulsification method. Systemic administration of SF2523

92
encapsulated nanoparticles inhibited the tumor growth, decrease desmoplasia
component, decrease the interstitial fluid pressure.

4.2

Future Directions
The findings presented in this dissertation showed that the combination therapy of

tubulin stabilizer and Hh inhibitor has the potential to treat advanced pancreatic cancer
associated with desmoplasia. The polymeric-drug conjugate micelles formulation can
ensure the efficient delivery of hydrophobic anticancer agent (DTX&CYP). Therefore, the
therapeutic efficacy would be improved compared to the parent drugs. However, different
aspects could be used to further improve our delivery system. Our system relies on
passive targeting, which is known as EPR phenomenon. This phenomenon is basically
extravasation of nano-sized agents into tumor sites through damaged tumor vasculature;
however, small portion of the drug could extravagate other organs (off targeting).
To further improve the current polymeric-drug conjugate platform, Attachment of
targeting moiety such as G11 can decrease the off-targeting delivery and improve the
delivery to the site of tumor. Moreover, the drug release profile is a limiting element for
effective treatment. As next direction, we will fabricate the polymer with glutathione (GSH)
responsive linker to be sensitive to the TME of PDAC.
Furthermore, we have shown that SF2523 that PI3K/BDR4 dual inhibitor had an excellent
efficacy in a pancreatic cancer mouse model; however, the premature release of SF2523
might cause less tumor accumulation. In future studies, we plan to redesign polymers that
have a function group, and synthesize drug analog with a functional group for conjugation
that allows having high tumor accumulation and less toxic to other tissues after systemic
administration
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